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THE BEST OF BOTH WORLDS:
APPLYING FEDERAL COMMERCE
AND STATE POLICE POWERS
TO REDUCE PRESCRIPTION
DRUG ABUSE
MICHAEL C. BARNES*
GRETCHEN ARNDT**
I. INTRODUCTION
Prescription drug1 abuse is the fastest growing drug problem in the United
States.2 Although public perception sees prescription medications as inherently
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1. Noteworthy prescription medications that are often abused include opioids (such as
hydrocodone and oxycodone), stimulants (such as dextroamphetamine and methylphenidate), and
benzodiazepines (such as alprazolam and diazepam). These medications are all classed as controlled
substances under federal and most states‘ laws. Controlled substances are drugs, substances, or
immediate precursors of drugs that the government has determined it must regulate because of their
potentially dangerous effects. See 21 U.S.C. § 802(6) (2011) (defining ―controlled substance‖); 21
C.F.R. § 1308.11–15 (2011) (listing current controlled substances in Schedules I–V). This Article
addresses a federal Controlled Substances Act amendment applicable to controlled substances in
Schedules II–V. 21 U.S.C. § 801 (2011). This Article often focuses on opioid pain medications because
these pain relievers are the most commonly abused controlled substances. Nevertheless, solutions to
prescription drug abuse must also apply to stimulants and benzodiazepines. See Andria Simmons, Ga.
Drug Overdose Deaths Drop: Fatalities off 9% from Prescriptions, Illegal Narcotics, GBI Reports,
ATLANTA J. CONST., Aug. 15, 2012, at B2 (stating that ―the anti-anxiety drug alprazolam, also known as
Xanax, topped the list of drugs most commonly found in . . . toxicology tests‖ for individuals who died
of prescription drug-related overdoses); SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S.
DEP‘T OF HEALTH & HUMAN SERVS., RESULTS FROM THE 2011 NATIONAL SURVEY ON DRUG USE AND
HEALTH: SUMMARY OF NATIONAL FINDINGS (2012), available at http://www.samhsa.gov/
data/nsduh/2k11results/nsduhresults2011.htm (stating that ―the most prevalent category of misused
prescription drugs is pain relievers‖). As discussed in the National Prescription Drug Abuse Prevention
Strategy, ―successful responses to prescription opioid diversion, misuse, and abuse will likely also be
applicable to other classes of medications.‖ CTR. FOR LAWFUL ACCESS & ABUSE DETERRENCE,
NATIONAL PRESCRIPTION DRUG ABUSE PREVENTION STRATEGY: 2011-2012 UPDATE 9 (2012),
available at http://www.claad.org/downloads/CLAAD_Strategy2011_v3.pdf.
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safer than illicit street drugs,3 prescription opioids caused 14,800 deaths in 2008, 4
which is more than cocaine and heroin combined. 5 Prescription drug abuse is even
more prevalent than most illicit drug use, and prescription drug-related deaths have
increased over 300-fold from 1999 to 2008.6 These staggering figures have
prompted the U.S. Centers for Disease Control and Prevention to call prescription
drug abuse a national epidemic,7 have prompted the current Presidential
Administration to respond to the problem with a prescription drug abuse prevention
plan,8 and have prompted state governors and attorneys general to develop statespecific task forces and plans.9

2. Leonard Paulozzi et al., CDC Grand Rounds: Prescription Drug Overdoses – a U.S. Epidemic,
61 Morbidity & Mortality Wkly. Rep. (CTRS. FOR DISEASE CONTROL & PREVENTION, ATLANTA, GA.),
JAN. 13, 2012, AT 10, 10. Consistent with the National Prescription Drug Abuse Prevention Strategy, this
Article regards as imprecise the Substance Abuse and Mental Health Services Administration‘s National
Survey on Drug Use and Health (NSDUH) definition of nonmedical use of prescription medications,
which is ―use without a prescription of the individual‘s own or simply for the experience or feeling the
drugs caused.‖ SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH &
HUMAN SERVS., supra note 1. This definition of nonmedical use does not differentiate between misuse
and abuse. Id. In Katz et al., Challenges in the Development of Prescription Opioid Abuse-Deterrent
Formulations, 23 CLINICAL J. PAIN 648 (2007), the definition(s) of misuse and abuse are more precise.
Katz et al. define misuse as ―use of medication (for a medical purpose) other than as directed or as
indicated, whether willful or unintentional, and whether harm results or not.‖ Id. at 650. The authors
define abuse as ―the intentional self-administration of a medication for a nonmedical purpose such as
altering one‘s state of consciousness, eg, getting high.‖ Id. Katz et al.‘s well-delineated definitions
should be used when describing misuse and abuse. For the general purposes of this article, however, we
will often use the phrase ―prescription drug abuse‖ to encompass these various related definitions.
3. Prescription
Drug
Abuse,
OFFICE
OF
NAT‘L
DRUG
CONTROL
POL‘Y,
http://www.whitehouse.gov/ondcp/prescription-drug-abuse (last visited May 7, 2013) (―Some
individuals who misuse prescription drugs, particularly teens, believe these substances are safer than
illicit drugs because they are prescribed by a healthcare professional and dispensed by a pharmacist.‖).
4. Margaret Warner et al., Drug Poisoning Deaths in the United States, 1980–2008, 81 NCHS
DATA BRIEF (Nat‘l Ctr. for Health Statistics, Hyattsville, Md.), Dec. 2011, at 1, 3.
5. Id.
6. See id. (reporting that ―drug poisoning deaths involving opioid analgesics‖ more than tripled
from about 4,000 in 1999 to 14,800 in 2008).
7. Paulozzi et al., supra note 2, at 10.
8. Press Release, Ctrs. for Disease Control & Prevention, Prescription Painkiller Overdoses at
Epidemic Levels (Nov. 1, 2011), available at http://www.cdc.gov/media/releases/2011/p1101_flu
_pain_killer_overdose.html.
9. See, e.g., N.M. STAT. ANN. § 24-2D-5.2 (LexisNexis 2007 & Supp. 2012) (requiring quarterly
prescription drug misuse and overdose prevention and pain management advisory council meetings to
discuss education of professional prescribers in New Mexico, among other issues); Press Release, Office
of the Att‘y Gen. of Ky., Attorney General‘s Statewide Prescription Drug Abuse Task Force Marks 2nd
Anniversary (Aug. 31, 2011) (touting the many accomplishments a state task force has made combating
Kentucky‘s prescription drug problem), available at http://migration.kentucky.gov/newsroom/ag/
taskforce2ndanniversary.htm; OHIO PRESCRIPTION DRUG ABUSE TASK FORCE, FINAL REPORT: TASK
FORCE RECOMMENDATIONS 5 (2010) (developing twenty policy recommendation to curb Ohio
prescription drug epidemic), available at http://www.odh.ohio.gov/~/media/ODH/ASSETS/Files/web%
20team/features/drug%20overdose/opdatffinalreport.ashx.
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Yet one hundred million patients in the U.S. suffer from chronic pain; 10 many
are worried about access to medications that have become a vital part of their
palliative care.11 State-licensed health care providers serve as the gatekeepers for
federally regulated medications.12 These practitioners13 face the conflict of treating
patients in pain—an invisible symptom—and fearing discipline for improperly
prescribing pain medication.14 Even more disturbing is the fact that many
physicians have never received the proper education or training to understand the
consequences of prescribing controlled substances or how to take steps to prevent
serious harm to their patients who are taking such medications. 15 Through
mandatory education, physicians can learn how to adequately treat their patients
while preventing abuse.16
While some state legislatures have taken proactive steps to prevent
prescription drug abuse by requiring mandatory prescriber education, many have
not.17 Prescriber education is needed on a national level. 18 Moreover, the solution to
the prescription drug abuse problem must address patient health, safety, and
welfare under the purview of the states‘ plenary police powers, and movement of
controlled substances through federally governed interstate commerce. 19 This
Article proposes action that harnesses the state and federal systems to provide a

10. INST. OF MED., RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION,
CARE, EDUCATION, AND RESEARCH 1 (2011).
11. See Donna Leinwand Leger, FDA Might Tighten Reins on Vicodin, USA TODAY (Jan.10, 2013,
8:55 AM), http://www.usatoday.com/story/news/nation/2013/01/09/fda-might-tighten-reins-on-vicodin/
1822211/.
12. See 21 U.S.C. § 822 (2011) (requiring anyone who distributes controlled substances to register
with the U.S. Attorney General prior to distribution).
13. ―Practitioners‖ and ―prescribers‖ refer to prescribing health care practitioners, including
physicians, physician assistants, nurse practitioners, and dentists. See DRUG ENFORCEMENT ADMIN.,
U.S. DEPT. OF JUSTICE, PRACTITIONER‘S MANUAL: AN INFORMATIONAL OUTLINE OF THE CONTROLLED
SUBSTANCES ACT 18 (2006) (defining practitioners to include ―physicians, dentists, veterinarians and
other registrants authorized to prescribe, dispense, and administer controlled substances‖).
14. H. Westley Clark & Karen Lea Sees, Opioids, Chronic Pain, and the Law, 8 J. PAIN &
SYMPTOM MGMT. 297, 304 (1993).
15. See Laxmaiah Manchikanti, National Drug Control Policy and Prescription Drug Abuse: Facts
and Fallacies, 10 PAIN PHYSICIAN 399, 417 (2007) (noting that there is a lack of education among
physicians regarding prescribing controlled substances and that surveys show that this lack of
knowledge leads to improper use of prescriptions).
16. See id. at 420–21 (suggesting mandatory education for medical schools and residency programs
on controlled substances, followed by continuing education each year, as a solution to the current lack of
knowledge on proper prescribing of opioids among physicians).
17. See infra Part V.A (explaining that California, Massachusetts, Michigan, Oregon, and
Tennessee all require some pain management or prescribing training for practitioner licensure).
18. See OFFICE OF NAT‘L DRUG CONTROL POL‘Y, OFFICE OF THE PRESIDENT, EPIDEMIC:
RESPONDING TO AMERICA‘S PRESCRIPTION DRUG ABUSE CRISIS, EXECUTIVE OFFICE OF THE PRESIDENT
OF THE UNITED STATES 2, 3 (2011) (suggesting amending federal laws to require certain training on
opioid prescribing practices for all prescribers).
19. See infra Parts III, IV.A (discussing states‘ plenary police powers and federal authority under
the Commerce Clause).
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comprehensive, effective solution: the Controlled Substances Act (CSA)20 must
require prescribers to obtain education and training on safe prescribing and abuse
prevention methods before they may register to prescribe controlled substances. 21
By establishing mandatory education for every controlled substance prescriber
nationwide pursuant to the CSA, the federal government is not encroaching on
states‘ plenary police power because such action is authorized under the Commerce
Clause of the United States Constitution.22
Part II of this Article discusses changes in prescribing practices and the need
to educate prescribers, the gatekeepers of the supply of controlled substances. Part
III discusses states‘ authority to regulate the practice of medicine, providing an
overview of states‘ plenary police power.23 Part IV discusses federal authority to
regulate controlled substances. This includes an overview of the Commerce Clause,
an overview of the CSA, and relevant case law that establishes the federal
government‘s authority to mandate prescriber education pursuant to the Commerce
Clause. Part V looks at other attempts to impose a prescriber education
requirement. Part VI proposes how such an education requirement should work and
uses Massachusetts and Virginia as models to show how a prescriber education
mandate would fit into current state systems. Part VII discusses how the prescriber
requirement will empower health care providers to prescribe appropriately, improve
patient treatment, and reduce liability. This national effort will be successful
because it will reach all controlled substance prescribers, and because it provides a
way for the federal government to enhance its regulation of commerce without
encroaching on states‘ plenary police powers.
II. INTERRUPTING SUPPLY BY EDUCATING PRESCRIBERS
Over the past two decades, prescribers have generally been more willing to
treat patients using controlled substances. 24 Given the current prescription drug
abuse epidemic, prescribers must be more cautious in treating people with pain and
other conditions for which controlled substances may be prescribed.25 This Part

20. 21 U.S.C. §§ 801–971 (2011) (controlling the manufacture and distribution of controlled
substances); see infra Part IV.A.1 (describing the current application of the CSA).
21. See infra Parts VI, VII.
22. See infra Part III.C (discussing the judicial decisions on the Commerce Clause and the states‘
plenary power).
23. See infra Part III; see also United States v. Lopez, 514 U.S. 549, 566 (1995) (referencing Art. I,
§ 8 of the U.S. Constitution, which lists the powers of Congress, and therefore withholds from Congress
and reserves for the states ―a plenary police power that would [if not withheld from Congress] authorize
enactment of every type of legislation‖).
24. See Barry Meier, Tightening the Lid on Pain Prescriptions, N.Y. TIMES, Apr. 9, 2012, at A1
(discussing the recent increase in prescription of controlled substances, such as opioids, despite limited
evidence on their effectiveness).
25. See Laxmaiah Manchikanti, Prescription Drug Abuse: What is Being Done to Address This
New Drug Epidemic? Testimony Before the Subcommittee on Criminal Justice, Drug Policy and Human
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discusses those changes in controlled substance prescribing, highlights the problem
of practitioners receiving inadequate training on how to safely prescribe, and
establishes the need for an education requirement.
A. Changes in Prescribing Opioids
Opioid medications relieve pain by reducing the effects of a painful stimulus
in the part of the brain that feels emotions.26 Until about fifteen years ago, opioids
were routinely prescribed only for end-of-life care, for cancer, and after surgery. 27
Since then, pain care experts and organizations at the state and national level began
emphasizing the importance of pain management.28 These experts and
organizations have made a case for using opioids to also treat chronic pain because
some patients experience a reduction in pain with long-term opioid use.29 Although
many health care professionals now prescribe opioids to treat chronic pain, studies
suggest that physicians may prescribe opioids too quickly, that opioids may
ultimately be ineffective for chronic pain, and that such medication may pose
serious health risks.30 For instance, researchers have linked opioid use to increased
sensitivity to pain, negative immune effects, sleep apnea, suppression of sexual
hormone production, increased elderly falls and hip fractures, and overdose
deaths.31 Additionally, opioids can be addictive and can lead to psychological
dependence,32 leading many pain-care physicians to question the legitimacy of
opioid use for treatment of chronic pain. 33 In fact, medical journals report that

Resources, 9 PAIN PHYSICIAN 287, 306 (2006) (illustrating the need for physicians to carefully consider
risks in prescribing certain pain medication).
26. See NAT‘L INST. ON DRUG ABUSE, NIH PUB. NO. 11-4881, PRESCRIPTION DRUGS: ABUSE AND
ADDICTION 2 (2011), available at http://www.drugabuse.gov/sites/default/files/rrprescription.pdf
(describing the way opioids affect the brain as pain relievers).
27. See Meier, supra note 24; Diane E. Hoffmann & Anita J. Tarzian, Achieving the Right Balance
in Oversight of Physician Opioid Prescribing for Pain: The Role of State Medical Boards, 31 J.L. MED.
& ETHICS 21, 21 (2003) (discussing the evolution of treating pain with opioids).
28. See Meier, supra note 24 (discussing state and federal efforts to make opioid use safer). In
2001, at the national level, the Joint Commission on Accreditation of Healthcare Organizations
(JCAHO), the ―Joint Commission‖ promulgated mandatory ―unproven‖ pain management guidelines.
See Manchikanti, supra note 15, at 409 (suggesting that combined factors, including support for pain
management requirements from national organizations and state medical boards, as well as advances in
science have led to a push for more prescribing).
29. See Manchikanti, supra note 15, at 409 (noting the widespread push to use opioids for chronic
pain).
30. See Paulozzi et al., supra note 2, at 11 (discussing a study finding that opioids did not provide
meaningful health benefits among injured workers); Jon Coppelman, Opioid Catastrophe: The Data
Leads
to
Doctors,
WORKERS‘
COMP
INSIDER
(Mar.
4,
2013,
1:30
PM),
http://www.workerscompinsider.com/2013/03/opioid-catatrop.html (calling data on prescribed opioid
use and effects among injured workers ―alarming‖).
31. See Meier, supra note 24; Manchikanti, supra note 15, at 409–10.
32. See Meier, supra note 24.
33. See PHYSICIANS FOR RESPONSIBLE OPIOID PRESCRIBING, CAUTIOUS, EVIDENCE-BASED OPIOID
PRESCRIBING 1–3 (2012), available at http://www.supportprop.org/educational/PROP_Opioid
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between four percent and twenty-six percent of those who take opioids for longterm pain treatment become addicted.34
Prompted by recent investigative journalism revealing strong ties between
pharmaceutical companies and both medical professionals and organizations that
have promoted expanded uses of opioids for pain treatment, 35 in May 2012, the
U.S. Senate Finance Committee began an investigation into ties between industry
funding and the groups backing the increased prescribing of opioid pain relievers. 36
The investigative reporting, Senate inquiries, and other recent events suggest that
prescribing standards may be in flux. As such, there is a need to properly educate
and train physicians on how to properly prescribe controlled substances.
B. The Need to Educate Prescribers
Practitioners are gatekeepers to the supply of prescription medications,
including controlled substances.37 Both legitimate and illicit users cannot gain
access to these medications until practitioners write prescriptions. 38 Consequently,
approximately ninety-five percent of the supply for non-medical users comes from
prescribers.39 Yet, studies show that physicians typically receive little to no
education or training in medical school on how to create proper pain management
treatment plans, and on how to recognize signs of prescription drug diversion,
misuse, and abuse.40 Although many general practitioners prescribe controlled

Prescribing.pdf (describing the lack of evidence on long-term efficacy of opioid treatment and how it
contributes to physicians‘ reluctance to prescribe opioid treatment).
34. Id.
35. See Charles Ornstein & Tracy Weber, The Champion of Painkillers, PROPUBLICA (Dec. 23,
2011, 2:15 PM), http://www.propublica.org/article/the-champion-of-painkillers (describing the ties
between pharmaceutical companies and medical professionals and organizations).
36. Press Release, Comm. on Finance, U.S. Senate, Baucus, Grassley Seek Answers about Opioid
Manufacturers‘ Ties to Medical Groups (May 8, 2012), available at http://www.finance.senate.gov/
newsroom/chairman/release/?id=021c94cd-b93e-4e4e-bcf4-7f4b9fae0047.
37. See Manuel Vallée, Bypassing the Gatekeepers: Selling Prescription Drugs Directly to
Consumers 5 (Ctr. For Culture, Org., and Politics, Working Paper No. 2008-03, 2008), available at
http://www.irle.berkeley.edu/culture/papers/Vallee08.pdf.
38. 21 U.S.C. § 829 (2011).
39. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & HUMAN
SERVS., supra note 1 (noting that 1.9% of nonmedical users got their drugs from ―a drug dealer or other
stranger‖ while 0.3% purchased the drugs on the Internet). Approximately fifty-four percent of
prescription pain drug abusers obtained the drug from a friend or relative, and the friend or relative
presumably obtained the drug through a valid prescription. Id. Another 18.1% of non-medical users
obtained their prescriptions from one physician. Id.
40. A national survey of residency programs in 2000 found that fifty-six percent of medical
residency programs required substance use disorder training, ranging from three to twelve hours. OFFICE
OF NAT‘L DRUG CONTROL POL‘Y, supra note 18, at 3. See also Diane E. Hoffmann, Treating Pain v.
Reducing Drug Diversion and Abuse: Recalibrating the Balance in Our Drug Control Laws and
Policies, 1 ST. LOUIS U. J. HEALTH L. & POL‘Y 231, 285 (2008) (noting that a study found that
physicians only correctly identified ten percent of patients who were pretending to be patients to obtain
opioid prescriptions in the study setting).
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substances, typically only practitioners who specialize in addiction treatment and
other similar specialties receive training in opioid prescribing and substance abuse
prevention and detection.41
Medical malpractice decisions are often conditioned on the practitioner‘s
adherence or non-adherence to common law standards of care and treatment
guidelines.42 Prescribers may oppose mandatory training requirements or guidelines
for fear of the threat of malpractice liability that may result from failing to adhere
to such standards and guidelines.43 Furthermore, they may perceive legal rules and
guidelines as a threat to their ability to use professional discretion. 44 However, such
fear shows an even greater need for in-depth education, not only on how to
properly prescribe controlled substances, but on the realistic repercussions that
practitioners may face for improperly prescribing.
Even though practitioners may find it unfavorable, mandatory education and
training for all who prescribe controlled substances is vital. Practitioners set the
standard of care in their field because the test for liability looks to, among other
facts, whether a practitioner followed an objectively reasonable standard of care in
the community at issue.45 With millions of Americans reporting chronic pain and
use of prescribed controlled substances,46 and approximately 15,000 deaths
41. OFFICE OF NAT‘L DRUG CONTROL POL‘Y, supra note 18, at 2–3.
42. See Michelle M. Mello, Of Swords and Shields: The Role of Clinical Practice Guidelines in
Medical Malpractice Litigation, 149 U. PA. L. REV. 645, 660, 667 (2001) (noting that many states use
custom as the standard of care for medical malpractice cases and discussing the use of practice
guidelines in medical malpractice litigation).
43. See Sandra H. Johnson, Regulating Physician Behavior: Taking Doctors’ “Bad Law” Claims
Seriously, 53 ST. LOUIS U. L.J. 973, 1001–03 (2009) (suggesting that alleged malpractice, even if a
physician is later exonerated, can chill prescribing); Hoffmann & Tarzian, supra note 27, at 21. Courts
usually use a four-pronged test, where following a reasonable standard of care is part of the duty and
breach of duty elements. See, e.g., Conrad-Hutsell v. Colturi, No. L-01-1227, 2002 WL 1290844, at *2,
*1 (Ohio Ct. App. May 24, 2003) (using a medical malpractice test comprised of 1) duty, 2) breach of
duty, 3) proximate cause; and 4) damages); McCarroll v. Reed, 679 P.2d 851, 854 (Okla. Civ. App.
1983) (using a medical malpractice test of duty, including the physician‘s obligation to use reasonable
professional care and skill, breach of duty, and injury caused by the breach).
44. See Johnson, supra note 43, at 974–75 (arguing that some laws intended to help patients may
actually have the effect of harming patients by negatively impacting medical decision making).
45. Complying with the objective standard of care in the medical community in which the
practitioner practices is important to assessing reasonableness, and therefore, non-negligence. See C.
Jerry Willis, Establishing Standards of Care: Locality Rules or National Standards, AAOS NOW (Feb.
2009), http://www6.aaos.org/news/PDFopen/PDFopen.cfm?page_url=http://www.aaos.org/news/ aaos
now/feb09/managing9.asp (explaining that twenty-nine states and Washington, D.C., use a national
standard of care, while twenty-one states use a locality standard of care). Compare State Bd. of Med.
Examiners v. McCroskey, 880 P.2d 1188, 1194–95 (Colo. 1994) (applying a generally accepted,
objectively reasonable standard of care and rejecting the prior determinations of standard of care based
on prevailing practices in the defendant physician‘s community), with Schaefer v. Larsen, 688 S.W.2d
430, 432 (Tenn. Ct. App. 1984) (explaining that the standard of care is defined relative to the standard
accepted by physicians in the community in which the defendant physician practices or by those in a
similar community).
46. See generally INST. OF MED., supra note 10 (explaining that pain is a public health crisis and
exploring the patient care, education, and research challenges of pain treatment).
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resulting from opioid abuse per year,47 now, more than ever, physicians need
education on standards of care in controlled substance prescribing. Mandatory
education will equip good-intentioned prescribers with the knowledge to properly
treat patients while recognizing and preventing diversion, misuse, and abuse. 48
Practitioners can be held criminally or civilly liable if they fail to properly
exercise a reasonable standard of care.49 To meet the standard of care, practitioners
must possess a ―reasonable degree of learning and skill which is ordinarily
possessed by others of the profession.‖ 50 Reasonable care includes maintaining a
familiarity with appropriate treatment standards articulated by laws and
guidelines,51 properly assessing a patient‘s medical history, 52 especially when
prescribing controlled substances, 53 which are riskier by definition;54 and
prescribing medications appropriately. 55 Courts look to practice guidelines, expert

47. See Warner et al., supra note 4, at 5.
48. See infra Part VI (proposing an education requirement and using Massachusetts and Virginia as
models).
49. PETER P. BUDETTI & TERESA M. WATERS, KAISER FAM. FOUND., MEDICAL MALPRACTICE
LAW IN THE UNITED STATES 1–4 (2005), available at http://kaiserfamilyfoundation.files.wordpress.com/
2013/01/medical-malpractice-law-in-the-united-states-report.pdf (explaining that state statutes and tort
law govern medical malpractice cases); see also Maia Szalavitz, Perspective: Why Did Conrad Murray
Just Get Four Years in Jackson’s Death?, TIME (Nov. 30, 2011), http://healthland.time.com/
2011/11/30/perspective-why-did-conrad-murray-get-just-four-years-in-jacksons-death/ (comparing Dr.
Murray‘s criminal sentence of four years for involuntary manslaughter due to his role in Michael
Jackson‘s death with the twenty-five to thirty-year criminal sentences two physicians faced for drug
dealing charges related to prescribing medications to patients who lied about their pain).
50. Artist v. Butterweck, 426 P.2d 559, 561 (Colo. 1967).
51. See Moss v. Taglieri, 842 A.2d 280 (N.J. Super. Ct. App. Div. 2004) (holding that a physician
violated the appropriate standard of care by knowingly prescribing medication doses well above the
limits allowed under regulations promulgated under the New Jersey Controlled Dangerous Substances
Act); Hoffmann & Tarzian, supra note 27, at 26 (reporting the results of a 2001 survey of state medical
boards finding that the majority of boards would investigate a practitioner who failed to prescribe
medications according to state guidelines).
52. See Watkins v. United States, 589 F.2d 214, 219 (5th Cir. 1979) (affirming a decision finding a
physician negligent for failing to conduct a full medical history in prescribing Valium to treat insomnia
and mild anxiety); Conrad-Hutsell v. Colturi, No. L-01-1227, 2002 WL 1290844, at *1, *6 (Ohio Ct.
App. May 24, 2003) (discussing charges against a physician accused of negligence for prescribing
narcotics to a patient suffering from Crohn‘s disease without seeking a complete medical history).
53. See Osborne v. United States, 166 F. Supp. 2d 479, 498–99 (S.D.W. Va. 2001) (explaining that
the physicians in that case should not have continued prescribing potentially addictive medications to a
patient with a known history of substance abuse).
54. See Controlled Substance Act, 21 U.S.C. § 801(2) (2011) (suggesting that, if unregulated, the
use of controlled substances could have a ―substantial and detrimental effect on the health and general
welfare of the American people‖).
55. Conrad-Hutsell, 2002 WL 1290844, at *6 (listing duties required of all physicians when
prescribing narcotics, including an inquiry into whether the practitioner was aware of the characteristics
of the drug; knew the patient‘s medical history and current condition; warned the patient of risk and side
effects of the drug; and prescribed drugs in the correct dose, for correct durations, and administered the
drug properly; and monitored the patient); see also Ballenger v. Crowell, 247 S.E.2d 287, 293–95 (N.C.
Ct. App. 1978) (discussing negligence claims against a physician whose patient became strongly
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opinion,56 state laws and regulations,57 and medical drug reference books58 to
determine whether a practitioner‘s treatment is in accordance with the standard of
care. Therefore, prescribers must obtain a proper education and training on
prescribing guidelines, laws, and standards.
Without the proper education and training, practitioners are more likely to
breach the standard of care because they are not fully aware of the duties imposed
up on them. They are more likely to improperly prescribe medications, which can
result in diversion, misuse, and abuse, and also result in actions against the
practitioner for medical malpractice or criminal liability. 59
With the proper training and education, practitioners can improve their
controlled substance prescribing behaviors, protect patients and communities, and
avoid liability. As such, mandatory prescriber education is necessary. Yet,
advocates of prescriber education must also get over the hurdle of proving that such
a requirement under the CSA does not encroach on states‘ plenary police power—a
hurdle that this Article establishes can be overcome.
III. STATE AUTHORITY TO REGULATE THE PRACTICE OF MEDICINE
Controlled substances are regulated, both at the federal level through the
and at the state level through state controlled substances acts, which can lead
to differences in regulation from state to state. 61 Regulating the use of controlled
substances is arguably activity that falls under states‘ plenary police power because
it pertains to states‘ rights to regulate the health, safety, and welfare of their
CSA60

addicted to prescription drugs after relying on the physician‘s advice that the patient would always have
to take such medication to treat a neurological condition).
56. See LAUREN KROHN, CAUSE OF ACTION AGAINST PHYSICIAN FOR NEGLIGENCE IN
PRESCRIBING DRUGS OR MEDICINES, 9 CAUSES OF ACTION § 25 (2013) (stating that it is generally
necessary for litigants to provide expert testimony in assisting the trial court in its determination of
whether care was appropriate in medical malpractice cases).
57. See infra note 40 and accompanying text (discussing state laws and regulations of controlled
substances).
58. See Roland v. Tedesco, 616 So. 2d 780, 785 (La. Ct. App. 1993) (using the physician‘s
reference to the Manual of Medical Therapeutics and other medical literature during the patient‘s twohour visit to the emergency room as evidence of the appropriateness of care); Taglieri v. Moss, 842 A.2d
280, 283 n.8 (N.J. Super. Ct. App. Div. 2004) (citing the Physicians’ Desk Reference for an explanation
of the drugs Percocet and Tylox); Osborne v. United States, 166 F. Supp. 2d 479, 498–99 (S.D.W. Va.
2001) (referring to the Physicians’ Desk Reference to conclude that the physician should not have
continued to prescribe addictive controlled substances to his patient who had a known history of
substance abuse).
59. See David B. Brushwood et al., Balance and the adoption of Abuse-Deterrent Opioid
Formulations in Pain Management Practice, 1 U. INCARNATE WORD PHARMACY REV. (2012),
available at http://uiwpharmacyreview.com/index.php/uiwpr/article/view/11/33 (noting that if patients
are harmed health care practitioners face the possibility of civil liability lawsuits or criminal charges).
60. 21 U.S.C. §§ 801–971 (2011).
61. See Hoffmann, supra note 40, at 274 n.322 (stating that almost every state has a controlled
substance statute similar to the CSA).
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citizens.62 Therefore, it would appear that a conflict exists between states‘ rights
and the purview of the federal government. To understand this conflict, it is
important to understand states‘ rights first. This Part provides an overview of
constitutional doctrine of states‘ plenary police power.
Under the Tenth Amendment of the U.S. Constitution, powers not specifically
granted to the federal government or prohibited to the states are reserved to the
states.63 States have an inherent authority to impose regulations on the private
rights of their citizens in order to protect their citizens‘ health, safety, and welfare. 64
This authority is referred to as ―state plenary police power.‖65
The authority to regulate the practice of medicine, in particular, falls under
the purview of states‘ plenary police power rather than under the authority of the
federal government.66 For example, in State v. Gee, William R. Gee was an aspiring
chiropractor in Arizona who practiced chiropractic science without first complying
with the requirements under state law. 67 In order to practice, Mr. Gee needed a
certificate in basic sciences and a license from the State Board of Chiropractic
Examiners.68 Of note, Mr. Gee claimed that the technical requirements prescribed
by the Arizona Basic Science Act were unconstitutional because they violated the
due process clauses of the Fourteenth Amendment of the U.S. Constitution and the
Constitution of Arizona.69 He took issue with the vagueness of the term ―practice of
healing‖ in the Act, and the discretion given to the State Board of Examiners in
determining who passed the exam. 70 The United States Supreme Court ruled in
favor of the state, concluding that it is unquestioned that the state legislature ―has
the power and duty to control and regulate such professions and practices affecting
the public health and welfare.‖71 The Court established that states regulate the
practice of health care professions under their plenary police powers.72
IV. FEDERAL AUTHORITY TO REGULATE CONTROLLED SUBSTANCES
Although states have the authority to regulate the practice of medicine, the
federal government has concurrent authority to regulate some aspects of the
62. See Barsky v. Board of Regents, 347 U.S. 442, 449 (1954) (―It is elemental that a state has
broad power to establish and enforce standards of conduct within its borders relative to the health of
everyone there. It is a vital part of a state‘s police power. The state‘s discretion in that field extends
naturally to the regulation of all professions concerned with health.‖).
63. U.S. CONST. amend. X.
64. See United States v. E. C. Knight Co., 156 U.S. 1, 11 (1895) (noting state authority ―to protect
the lives, health, and property of its citizens, and to preserve good order and the public morals‖).
65. United States v. Lopez, 514 U.S. 549, 566 (1995).
66. Barsky, 347 U.S. at 449.
67. 236 P.2d 1029, 1030 (Ariz. 1951).
68. Id.
69. Id. at 1032–33.
70. Id.
71. Id. at 1033.
72. Id.
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practice of medicine as well; the federal government derives this power from the
Commerce Clause.73 This Part provides an overview of the Commerce Clause and
discusses how the federal government derives its authority to regulate controlled
substances pursuant to the Controlled Substances Act and its relevant case law. It
also discusses recent restrictions and their practical impact on the CSA.
A. The Controlled Substances Act and Federal Authority Under the Commerce
Clause
Before discussing the Commerce Clause, it is important to have an
understanding of what the CSA entails.
1. The Controlled Substances Act
In 1970, Congress enacted the Controlled Substances Act (CSA), a federal
law controlling the manufacture and distribution of controlled substances. 74 It
requires adherence to registration, storage, and record-keeping requirements for
those who manufacture, distribute, dispense, import, or export controlled
substances.75 The CSA attempts to ensure that records are kept of the handling of
controlled substances as they move down the supply chain from the manufacturer
to the end user.76
In 1973, Congress created the Drug Enforcement Administration (DEA)
under the CSA, and gave the agency the authority to schedule and regulate
controlled substances.77 Under the CSA, the DEA is responsible for preventing,
detecting, and investigating diversion of controlled substances while ensuring the
availability of these drugs for legitimate use. 78 The Act classifies controlled
substances using five schedules based on each drug‘s medical uses and potential for
abuse.79 The most dangerous controlled substances, such as heroin and synthetic
―bath salts,‖ are classified in Schedule I.80 Schedule I substances cannot be
prescribed under the CSA because, by definition, they have no accepted medical
use.81 Schedules II through V regulate drugs with medical uses that also have the
potential for abuse.82
73. U.S. Const. art. I, § 8, cl. 3.
74. 21 U.S.C. §§ 801–852 (2011).
75. Id.
76. See United States v. Rosenberg, 515 F.2d 190, 193 (9th Cir. 1975) (explaining that the CSA‘s
record system was intended to monitor the distribution of drugs).
77. Reorganization Plan No. 2 of 1973, 3 C.F.R. 785 (1971–1975), reprinted in 21 U.S.C. 801
(2011).
78. DEP‘T OF JUSTICE, http://www.justice.gov/jmd/mps/manual/dea.htm (last visited May 8, 2013)
(discussing the DEA‘s mission).
79. 21 U.S.C. § 812 (2011).
80. § 812(c).
81. § 812(b)(1).
82. § 812(b)(2)–(5).

282

JOURNAL OF HEALTH CARE LAW & POLICY

[VOL. 16:271

Prescribers licensed to practice in a state must register with the DEA every
three years in order to prescribe controlled substances in Schedules II through V.83
When prescribing controlled substances, registered practitioners must follow the
prescription-writing,84 order form,85 and record-keeping86 provisions of the CSA or
face penalties.87 Regulations under the CSA require that a controlled substance
prescription be dated and signed as of the date of issue. 88 The prescription must
include the patient‘s and practitioner‘s names and addresses; the practitioner‘s DEA
registration number; the drug‘s name, strength, and dosage form; the quantity
prescribed; the directions for use; and the number of refills. 89
In addition to civil and criminal liability at common law, under the CSA,
practitioners face criminal charges, including fines, revocation of licenses to
practice medicine, and imprisonment, for improperly prescribing controlled
substances.90 In order to avoid penalties, ―a prescription for a controlled
substance . . . must be issued for a legitimate medical purpose by an individual
practitioner acting in the usual course of his professional practice.‖ 91 When a
practitioner commits a violation, the DEA can prosecute the practitioner under the
CSA, or the practitioner may be prosecuted under state laws. 92 Tension exists
between medical practitioners and federal drug enforcement efforts because health
care practitioners see DEA interventions as a threat to their autonomy to practice
medicine in a way that best serves their patients. 93
Since the creation of the federal prescriber registration requirement, 94 the
government‘s commerce power has expanded.95 During the expansion, petitioners
83.
84.
85.
86.
87.

§ 823(g).
§ 829.
§ 828.
§ 827.
See OFFICE OF DIVERSION CONTROL, U.S. DEP‘T OF JUSTICE, PRACTITIONER‘S MANUAL: AN
INFORMATIONAL OUTLINE OF THE CONTROLLED SUBSTANCES ACT 18–22 (2006), available at
http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf.
88. Id.
89. Id.
90. 21 U.S.C. §§ 824, 841, 960, 962 (2011) (describing the penalties practitioners face for
improperly prescribing controlled substances).
91. 21 C.F.R. § 1306.04(a) (2005).
92. See supra note 49; Hoffmann, supra note 40, at 274 n.322.
93. See Hoffmann, supra note 40, at 256–57 (describing the rift between practitioners and the
government due to differing views on opioids and narcotics).
94. The controlled substance prescriber registration requirement originated under the Harrison Act,
which required manufacturers and distributors of narcotics to register with a local internal revenue
officer in order to control taxation of these substances. Harrison Narcotics Act, ch. 1, 38 Stat. 785
(1914), amended by the Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No.
91-513, 84 Stat. 1236 (1970).
95. See ERWIN CHEMERINSKY, CONSTITUTIONAL LAW: PRINCIPLES AND POLICIES 269 (4th ed.
2011) (stating that between 1936 and 1995, the Supreme Court did not invalidate a single federal law
under the Commerce Clause and that, additionally, the Court has rejected recent Commerce Clause
challenges to federal statutes).
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seized the opportunity to challenge the CSA‘s provisions that allow the federal
government to regulate medications in commerce. 96 However, the Supreme Court
has solidified the DEA‘s authority under the CSA to regulate controlled substances
in the stream of commerce.97 Even those who believe that the expansion of
Commerce Clause has gone too far can find that the federal government has the
authority to mandate a prescriber education requirement under the CSA.
2. The Commerce Clause
The U.S. Constitution authorized Congress ―[t]o regulate commerce with
foreign nations, and among the several states, and with the Indian tribes.‖ 98 Courts
have interpreted this to mean that Congress may regulate 1) the channels of
interstate commerce; 2) the instrumentalities of interstate commerce, including
persons and things in interstate commerce; and 3) economic activities that have a
substantial effect on interstate commerce.99 Other iterations of the Commerce
Clause test have been used since the first Supreme Court Commerce Clause case,
Gibbons v. Ogden, in 1824.100 Beginning with the third prong of the test and
moving in descending order, this section analyzes how the prescriber education
requirement is compatible with Congress‘s Commerce Clause power under all
prongs of the test used since 1971.
In the seminal case Gonzales v. Raich, the Supreme Court specifically upheld
section 801 of the CSA. 101 This section states that intrastate distribution of
controlled substances impacts interstate flow of controlled substances, and
therefore, the federal government has the authority to regulate intrastate flow of
controlled substances.102 Raich dealt with California‘s Compassionate Use Act,
which allowed individuals with serious medical conditions to use marijuana to treat
that condition upon a physician‘s determination that such treatment is

96. See, e.g., United States v. Rosenberg, 515 F.2d 190, 196–200 (9th Cir. 1975) (stating that
petitioner had several arguments, including that the CSA violated the Tenth Amendment); United States
v. Collier, 478 F.2d 268, 272 (5th Cir. 1973) (stating that petitioner argued that the CSA improperly
encroached upon the states‘ police powers under the Tenth Amendment).
97. See infra Part IV.A.2.
98. U.S. CONST. art. I, § 8, cl. 3.
99. See Gonzales v. Raich, 545 U.S. 1, 16–17 (2005) (articulating the three categories of activity
that Congress may regulate pursuant to its Commerce Clause powers). The Commerce Clause test used
in Raich was first articulated in Perez v. United States, 402 U.S. 146, 150 (1971).
100. 22 U.S. (9 Wheat.) 1 (1824). In Gibbons, the Court decided that the federal right to operate a
ferry under federal law trumped a New York state ferry boat law. Id. at 239–40. The Court interpreted
―among the several states‖ to mean that Congress can regulate intrastate waterways that have interstate
effects, and that commerce includes intercourse between parts of nations, not just exchange of
commodities. Id. at 194–95, 229–30.
101. 545 U.S. at 22.
102. See 21 U.S.C. § 801 (2011); see also 545 U.S. 21 n.32, 22 (discussing Congress‘s findings
regarding the interstate effects of intrastate commerce).
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appropriate.103 Yet, the CSA classifies marijuana as a Schedule I controlled
substance, meaning that it has no legally recognized medical function and that
physicians are not allowed to prescribe it.104 Per her physician‘s instructions, Angel
Raich grew marijuana at home to treat the effects of an inoperable brain tumor,
such as severe seizures and multiple chemical sensitivities, among other things. 105
The DEA took the opportunity to challenge the Compassionate Use Act by seizing
the doctor-prescribed marijuana from Raich‘s home. 106
The government argued that consuming locally grown marijuana for medical
purposes affects the interstate market of marijuana, and therefore, the federal
government may regulate it.107 The Supreme Court articulated the Commerce
Clause test, which empowers Congress to regulate the channels, instrumentalities,
and activities with substantial effects on interstate commerce. 108 Although the
home-grown marijuana was grown and used intrastate, it was a fungible product
indistinguishable from marijuana that illicitly passed through commerce, and it
could have moved into the national market.109 Therefore, it fell under the third
prong of the test, which allows the federal government to regulate activities with a
substantial effect on interstate commerce, and as such, the Court ruled the federal
government could regulate growing medical marijuana because this activity has
substantial effects on interstate commerce. 110
The federal government can also regulate prescription controlled substances
under the second prong of the Commerce Clause test because these drugs are
―things‖ in interstate commerce.111 In a 1969 case, Daniel v. Paul, the Supreme
Court determined that the federal government could regulate a recreational facility
in Arkansas pursuant to the Commerce Clause because three out of four items sold
at the facility‘s snack bar traveled in interstate commerce. 112 The Court established
that food is a ―thing‖ in commerce by showing that the ―principal ingredients going
into the bread [as well as certain ingredients in the soft drinks] were produced and
103. Compassionate Use Act of 1996, CAL. HEALTH & SAFETY CODE § 11362.5(b)(1)(A) (West
2012).
104. 21 U.S.C. § 812(b)(1) (2011).
105. Raich, 545 U.S. at 6–7; Brief for Respondents at *4, Raich, 545 U.S. 1 (No. 03-1454) (citing
statement of Frank Henry Lucido, M.D.).
106. Raich, 545 U.S. at 7.
107. See id. at 20.
108. Id. at 16–17.
109. See id. at 22 (finding that Congress was ―well within its authority‖ to regulate intrastate
marijuana as a ―fungible commodity‖); id. at 40 (Scalia, J., concurring) (explaining how drugs like
marijuana are fungible commodities).
110. See id. at 20–22 (majority opinion).
111. See id. at 16–17, 26 (describing the second prong of the Commerce Clause and explaining how
the CSA is within Congress‘s powers). Controlled substances contain components shipped in interstate
commerce or are themselves shipped in interstate commerce. See id. at 50 (O‘Connor, J., dissenting)
(asserting that most substances regulated under the CSA, unlike marijuana, require elements traveling in
interstate commerce).
112. 395 U.S. 298, 300, 305 (1969).
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processed in other States.‖113 The facility‘s snack bar sold hot dogs with buns,
hamburgers with buns, soft drinks, and milk, and so a ―substantial portion of the
food served in the snack bar [had] moved in interstate commerce.‖ 114 Therefore, the
snack bar food items were items in interstate commerce, and the lake facility that
sold them could be regulated under Congress‘s commerce power in conjunction
with the Civil Rights Act of 1964.115
Again, in United States v. Sullivan, Congress found that ―things‖ that had
traveled within commerce could be regulated by the commerce power. 116 In this
case, which was tried under the Federal Food, Drug and Cosmetic Act, Jordan
James Sullivan, a retail druggist, appealed misbranding charges that resulted when
he moved sulfathiazole tablets from a properly labeled container to containers
without proper instructions for use.117 At issue was whether the federal government
could regulate the drugs under the Commerce Clause if the drugs‘ manufacturers
had previously shipped the drugs in interstate commerce, even though Dr. Sullivan
only held them for intrastate sale.118 The Court found that, because the drugs had
previously traveled across state lines, they were considered ―things‖ in interstate
commerce under the commerce power, 119 and therefore, the Court found Dr.
Sullivan guilty of misbranding under federal law, even though the drugs were held
only for local, intrastate sale. 120
The proposed CSA Amendment requiring prescriber education is valid under
all three prongs of the Commerce Clause test. First, the federal government can
mandate a prescriber education requirement under the third prong of the Commerce
Clause, as in Raich.121 Practitioners, as gatekeepers along the supply chain of
prescription controlled substances, are engaging in an activity that could have a
significant impact on commerce. Like the marijuana in Raich that could travel
interstate after it was grown, controlled medications can move interstate after being
prescribed within a state. 122 With the proper education, physicians may change their

113. Id. (quoting the decision of the District Court below).
114. Id. (internal quotation marks omitted).
115. Id.
116. United States v. Sullivan, 332 U.S. 689, 697 (1948).
117. Id. at 690–92.
118. Id. at 692.
119. Id. at 697.
120. Id. at 697–98. The Court noted Congress‘s power ―under the commerce clause to regulate the
branding of articles that have completed an interstate shipment and are being held for future sales in
purely local or intrastate commerce.‖ Id. at 698.
121. Gonzales v. Raich, 545 U.S. 1, 25 (2005) (quoting United States v. Morrison, 529 U.S. 598, 610
(2000) (―Where economic activity substantially affects interstate commerce, legislation regulating that
activity will be sustained.‖).
122. See 21 U.S.C. § 801(4) (2011) (finding that local disbursement or possession of controlled
substances contributes to growth in the interstate traffic for such substances).
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prescribing habits, either prescribing more or fewer controlled substances. 123
Therefore, given the prescribers‘ substantial effects on commerce, Congress may
require that practitioners engage in mandatory training under the third prong of the
Commerce Clause test.124
Second, the federal government derives authority to issue a prescriber
education requirement through the second prong of the Commerce Clause test.125
Almost every controlled substance contains ingredients that move in interstate
commerce, similar to the snack bar ingredients in Paul.126 And, almost every
controlled substance is shipped through interstate commerce at some point before
use, similar to the medication in Sullivan.127 Therefore, like the food products sold
in Paul and the medications held for local sale in Sullivan, controlled substances
are things of interstate commerce that may be regulated under the second prong of
the Commerce Clause test.128 As Justice Scalia stated in Raich, it is ―self-evident‖
that items falling under the channels or instrumentalities of interstate commerce
prongs fall under the commerce test because they are the ―ingredients of interstate
commerce itself.‖129
Third, the federal government can obtain authority to mandate a prescriber
education requirement to regulate the gatekeepers of the supply of controlled
substances through the first prong of the Commerce Clause test that provides the
power to regulate the channels of interstate commerce.130 In Heart of Atlanta Motel

123. See, e.g., Michael E. Pichichero, Physician Education Intervention Influenced Prescribing for
Otitis Media, 8 J. MANAGED CARE PHARMACY 141, 144 (2005) (finding that after attending a
continuing medical education program, physicians significantly decreased inappropriate antibiotic
prescribing for a certain type of ear infection).
124. See, e.g., Wickard v. Filburn, 317 U.S. 111, 125 (1942) (stating that although the wheat at issue
was intended for private consumption, Congress may still exert power on activities not naturally
regarded as regulating commerce if the activities have a substantial effect on interstate commerce); see
also 21 U.S.C. § 871(a)(1) (2011) (authorizing the Attorney General to carry out educational and
training programs concerning drug abuse); Raich, 545 U.S. at 17 (highlighting the third prong of the
Commerce Clause test).
125. See, e.g., Daniel v. Paul, 395 U.S. 298, 305 (1969) (determining in that case that the Commerce
Clause is applicable because most of the snack bar food items contains elements that travelled
interstate); see also § 871(a)(1); Raich, 545 U.S. at 16–17 (noting that under the second prong, Congress
has authority to regulate and protect the instrumentalities of interstate commerce).
126. See 21 U.S.C. § 801(3) (2011) (acknowledging that controlled substances have a significant
effect on interstate commerce because many of the substances are transported in interstate commerce
after manufacture even if they are only intended for local distribution); Paul, 395 U.S. at 305 (finding
that three out of the four sold snack food items contained ingredients that originated outside the state).
127. See § 801(3)(B) (noting that even locally dispensed controlled substances are typically
transported in interstate commerce immediately prior to the disbursement); United States v. Sullivan,
332 U.S. 689, 698 (1948) (determining that Congress may regulate the branding of medication that has
completed an interstate shipment where it is being held for local distribution or intrastate commerce).
128. See supra notes 125–27 and accompanying text.
129. Raich, 545 U.S. at 34 (Scalia, J., concurring).
130. See 21 U.S.C. § 871(a)(1) (2011); id. at 12–13 (noting that Congress intended to prevent drugs
from entering illicit channels of commerce by enacting the CSA); see also Caminetti v. United States,
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v. United States, the Supreme Court upheld the constitutionality of the Title II of
the Civil Rights Act of 1964.131 It held that the law was a valid exercise of
congressional power to prohibit from discriminating by race when boarding
travelers. Congress has this authority ―to keep the channels of interstate commerce
free from immoral and injurious uses.‖ 132 These individuals responsible for
transporting others to the motel via channels of interstate commerce, such as
interstate roadways, could be regulated under the first prong of the commerce
test.133
Like the flow of travelers through the interstate channels of travel in Heart of
Atlanta Motel, controlled substances pass through an interstate supply chain from
manufacturer to distributor, to pharmacy, to patient. 134 The CSA was enacted to
regulate the national supply chain of controlled substances. 135 As stated in United
States v. Collier, a case upholding the constitutionality of the CSA, discussed
further below, the Fifth Circuit said:
. . . Congress fashioned the Comprehensive Drug Control Act to
provide ―a ‗closed‘ system of drug distribution for legitimate
handlers of such drugs. Such a closed system should significantly
reduce the widespread diversion of these drugs out of legitimate
channels into the illicit market, while at the same time providing the
legitimate drug industry with a unified approach to narcotic and
dangerous drug control.‖ 136
In keeping with this rationale for regulation under the CSA, practitioners need
mandatory education to fulfill their role as gatekeepers of potentially dangerous
medications in the channel of commerce. 137 If practitioners are not allowed or are
too afraid to prescribe, the channel is blocked. If practitioners overprescribe, the
channel is flooded. This analysis of regulating the gatekeepers of the supply of
controlled substances is consistent with the stance of those who believe that the
Commerce Clause has been interpreted too broadly. 138 Unlike the substantial

242 U.S. 470, 491 (1917) (noting Congress‘s authority to regulate the channels of interstate commerce
to keep them free from injurious uses).
131. 379 U.S. 241, 261 (1964).
132. Id. at 256 (quoting Caminetti, 242 U.S. at 491).
133. Id. at 255–56.
134. See id. at 256 (explaining that commerce among the states includes exchanges between citizens
and the transport of people and property).
135. See 21 U.S.C. 801 (2011).
136. 478 F.2d 268, 273 (1973) (citing H.R. REP. NO. 91-1444, 4566, 4571–72 (1970)).
137. See Public Policy Statement on Measure to Counteract Prescription Drug Diversion, Misuse
and Addiction, AM. SOC‘Y ADDICTION MED. (Jan. 25, 2012), http://www.asam.org/docs/publicy-policystatements/1-counteract-drug-diversion-1-12.pdf?sfvrsn=0 (arguing that increased education of health
practitioners would improve patient outcomes and curb misuse of controlled substances).
138. See generally Randy Barnett, The Original Meaning of the Commerce Clause, 68 U. CHI. L.
REV. 101 (2001) (providing one law scholar‘s argument that Congress‘s power under the Commerce
Clause should be narrowly construed).

288

JOURNAL OF HEALTH CARE LAW & POLICY

[VOL. 16:271

effects argument under the third prong, controlling the supply of potentially
injurious substances in commerce is fully within Congress‘s traditional commerce
power used since 1824, as held in Gibbons v. Ogden.139
The prescriber education mandate argument can also be made under the
Necessary and Proper Clause of the Constitution. 140 Under the Necessary and
Proper Clause, as forged by Justice Scalia in his concurrence to Raich, the federal
government can obtain authority to regulate the gatekeepers of the supply of
controlled substances.141 Justice Scalia agreed that Congress has the power to
regulate intrastate goods that could flow through interstate commerce. 142 But he
disagreed with the validity of the third prong of the Commerce Clause test because
he thought that activities that only have a substantial effect on interstate commerce
could not be justified as true things of interstate commerce. 143 Instead, he argued
that Congress‘s power over things not of interstate commerce derives from the
Necessary and Proper Clause of the Constitution.144 Justice Scalia found that the
CSA‘s provisions were necessary and proper in order to allow the federal
government to stop diversion and oversee proper supply of controlled
substances.145 The application of the Necessary and Proper Clause hinged on
whether the CSA was an appropriate means to allow the federal government to
achieve these goals.146 Justice Scalia suggested that preventing diversion was not a
violation of sovereignty of the sort that would be inappropriate, 147 and that it was
sufficient to authorize the application of the CSA to Angel Raich. 148 This reasoning
can be extended to require prescriber education to help ensure that controlled
substances stay within the appropriate chain of supply. Thus, a federal prescriber
education requirement is constitutional under both the Commerce Clause and the
Necessary and Proper Clause.

139. 22 U.S. (9 Wheat.) 1, 70–71 (1824).
140. See U.S. Const. art. I, § 8, cl. 18.
141. Gonzales v. Raich, 545 U.S. 1, 33–42 (2005) (Scalia, J., concurring) (noting that even if
intrastate activities do not substantially affect interstate commerce Congress can still regulate such
activities through the Necessary and Proper Clause).
142. Id. at 35.
143. Id. at 34.
144. Id. at 35 (―[W]here necessary to make a regulation of interstate commerce effective, Congress
may regulate even those intrastate activities that do not themselves substantially affect interstate
commerce.‖); U.S. CONST. art. I, § 8, cl. 18 (authorizing Congress to ―make all Laws which shall be
necessary and proper for carrying into Execution the foregoing Powers, and all other Powers vested by
this Constitution in the Government of the United States, or in any Department or Officer thereof‖).
145. Raich, 545 U.S. at 38.
146. Id. at 40.
147. Id. at 41.
148. Id. at 41–42.
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B. Recent Restrictions on Commerce Power Do Not Affect the CSA’s
Constitutionality
Commerce Clause jurisprudence includes a seventy-year period of restriction
beginning after the civil war in 1867 and continuing to 1937 when the Supreme
Court largely invalidated challenged federal laws. 149 From 1937150 until the mid1990s, the commerce power was unshaken and continued to expand through
Supreme Court findings.151 Then, a recent line of cases restricted the Commerce
Clause power.152 United States v. Lopez and United States v. Morrison addressed
whether noneconomic conduct can be construed as asserting substantial effects on
commerce through the third prong of the Commerce Clause test.153 National
Federation of Independent Business v. Sebelius addressed whether Congress may
compel commerce.154 The prescriber education mandate can be distinguished from
the regulations that were overturned in each of these cases.
In Lopez, Alfonso Lopez challenged the constitutionality of the federal GunFree School Zones Act of 1990 (the ―Act‖), which prohibited possessing a firearm
in a school zone.155 Alfonso Lopez, Jr., a twelfth-grade student, brought a
concealed gun to school to deliver it to another person in exchange for money. 156
After school authorities discovered he was carrying the weapon, he was charged
with violating the Act.157 Lopez argued that the federal statute was unconstitutional
―as it is beyond the power of Congress to legislate control over our public
schools.‖158 The government argued that the possession of a firearm in an
educational setting would substantially impact interstate commerce because it
149. See ERWIN CHEMERINSKY, CONSTITUTIONAL LAW: PRINCIPLES AND POLICIES 145–59 (3d ed.
2009) (discussing Commerce Clause jurisprudence during this time period).
150. The first case to begin changing the Commerce Clause doctrine was NLRB v. Jones & Laughlin
Steel Corp., 301 U.S. 1 (1937). See also James Gray Pope, The Thirteenth Amendment Versus the
Commerce Clause: Labor and the Shaping of American Constitutional Law, 1921–1957, 102 COLUM. L.
REV. 1, 88 (2002) (discussing the expansion of Congress‘s Commerce Clause powers between 1921 and
1957 in the context of labor law).
151. See CHEMERINSKY, supra note 149, at 159–83.
152. See United States v. Lopez, 514 U.S. 549, 567 (1995) (finding that possession of a gun in a
school zone is not economic activity that affects interstate commerce); United States v. Morrison, 529
U.S. 598, 613 (2000) (finding that Congress cannot regulate a noneconomic activity by saying that it
cumulatively has a substantial effect on interstate commerce); Solid Waste Agency v. United States
Army Corps of Eng‘rs, 531 U.S. 159, 174 (2001) (finding that Congress could not exercise Commerce
Clause powers to regulate intrastate land inhabited by migratory birds); Jones v. United States, 529 U.S.
848, 859 (2000) (finding that residences used for everyday living are not commercial activity regulated
under the Commerce Clause).
153. Lopez, 514 U.S. at 559–61; Morrison, 529 U.S. at 611, 617.
154. Nat‘l Fed‘n of Indep. Bus. v. Sebelius, 132 S. Ct. 2566, 2586 (2012) (noting that Congress‘s
power to regulate commerce reflects the understanding that Congress may not mandate economic
activity).
155. 514 U.S. at 551.
156. Id.
157. Id.
158. Id.
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would likely lead to a violent crime, which would then affect the general economic
condition by raising insurance costs and limiting the willingness to travel to an area
perceived to be unsafe.159 Unlike the case of prescribed controlled substances, there
was no evidence that Lopez‘s gun had traveled interstate or that the law at issue
would substantially affect commerce in guns because the law was specific to guns
near schools.160 Therefore, the Supreme Court rejected these arguments, finding
instead that the presence of a gun near a school was not economic activity. 161 It
held that, under the government‘s reasoning, Congress‘s power could extend over
almost anything, including ―criminal law enforcement or education where States
historically have been sovereign.‖162 Our case for the prescriber education
regulation can be distinguished because, as described above in Part IV.A., the
activity of releasing a supply of controlled substances to consumers does have
substantial effects on commerce, unlike the noneconomic possession of a gun near
a school in Lopez.
In Morrison, the Supreme Court found the Violence Against Women Act
(VAWA) unconstitutional based on Lopez.163 Christy Brzonkala alleged that she
was raped by Virginia Polytechnic Institute football players and sued for civil
damages under the VAWA, which provides a federal civil remedy for victims of
gender-motivated violence.164 After the defendants challenged the constitutionality
of VAWA, Brzonkala and the government argued that the VAWA should be
upheld under the third prong of the Commerce Clause. 165 They argued that gendermotivated violence affects interstate commerce by
deterring potential victims from traveling interstate, from engaging in
employment in interstate business, and from transacting with
business, and in places involved in interstate commerce; . . . by
diminishing national productivity, increasing medical and other
costs, and decreasing the supply of and the demand for interstate
products.166
The Supreme Court rejected Brzonkala‘s and the government‘s argument, and
found that the VAWA was unconstitutional because the acts of violence had only
an ―attenuated‖ effect on interstate commerce rather than a substantial one. 167
Moreover, the acts of violence only resulted in indirect economic consequences,

159. Id. at 563–64.
160. Id. at 567 (―Respondent was a local student at a local school; there is no indication that he had
recently moved in interstate commerce, and [under the law at issue] there is no requirement that his
possession of the firearm have any concrete tie to interstate commerce.‖).
161. Id.
162. Id. at 564.
163. United States v. Morrison, 529 U.S. 598, 602 (2000).
164. Id. at 604; 42 U.S.C. § 13981 (2011).
165. Morrison, 529 U.S. at 607.
166. Id. at 615 (internal citations omitted).
167. Id. at 612, 615, 617.
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and intrastate actions must be economic in nature to be viewed in aggregate by
courts.168 If cumulative effects of noneconomic activity could justify such as
economic activity, it would allow Congress to regulate any violent crime in the
country.169 Unlike those who commit violence against women, prescribers of
controlled substances do substantially affect interstate commerce by their
actions.170
The majority opinion in the recent Supreme Court case, Sebelius, found that
the federal government could not mandate health insurance under the Commerce
Clause.171 The case follows the line of cases that recognize limits of Congress‘s
Commerce Clause power.172 However, like Lopez and Morrison, which overturned
legislation that can be distinguished from the proposed legislation at hand on the
grounds that the regulations on guns near schools and violence against women,
respectively, were noneconomic regulations,173 the regulation in Sebelius can be
distinguished from that in the proposed CSA Amendment. 174 In Sebelius, the
Supreme Court held that the Affordable Care Act was not a valid embodiment of
the legislature‘s commerce power, and instead upheld the Act under Congress‘s
taxing power.175 The Act compels individuals to purchase health insurance or to
pay a fine for not purchasing insurance. 176 The rationale behind the law is that
many seemingly healthy people unexpectedly have health events requiring costly
medical care, and that these uninsured individuals raise costs for hospitals and
paying health insurance customers. 177
Justice Roberts‘ majority opinion found that the Constitution ―gave Congress
the power to regulate commerce, not to compel it.‖178 Because this law would
require those persons not currently acting in the health insurance market to engage
there, this law would be compelling specific commercial activity by individuals. 179

168. Id. at 613.
169. Id. at 615.
170. See supra Part IV.A (showing that health care providers are gatekeepers of the supply of
controlled substances, and both controlled substances and prescribers of controlled substances may be
regulated under Congress‘s Commerce Clause power).
171. Nat‘l Fed‘n of Indep. Bus. v. Sebelius, 132 S. Ct. 2566, 2593 (2012).
172. See supra Part IV.B (discussing Commerce Clause jurisprudence).
173. See supra notes 153–70 and accompanying text.
174. See Nat’l Fed’n of Indep. Bus., 132 S. Ct. at 2609–11 (Ginsburg, J., concurring) (discussing the
economic issues that the Patient Protection and Affordable Care Act was designed to regulate).
175. Id. at 2593, 2600 (majority opinion) (―The Affordable Care Act‘s requirement that certain
individuals pay a financial penalty for not obtaining health insurance may reasonably be characterized as
a tax.‖).
176. See id. at 2580.
177. Id. at 2585.
178. Id. at 2589 (emphasis in original).
179. See id. at 2590.
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The proposed prescriber education requirement does not compel commerce,
and therefore, is viable after the Sebelius ruling.180 Commerce related to controlled
substances has and will occur whether or not the proposed prescriber education
requirement is enacted. The mandate would require prescribers of controlled
substances to act and be educated in prescribing, but the regulation would only be
applied to practitioners who actively choose to act themselves, by registering to
prescribe controlled substances. Unlike the uninsured actors who will be compelled
to buy health insurance or pay a tax under the Affordable Care Act ―because they
are doing nothing,‖181 the prescribers that would be regulated under the education
mandate actively make the choice to prescribe controlled substances in commerce.
And, the commerce exists outside of the proposed regulation on prescribers. Like
other areas that have safety risks that cannot adequately be controlled without
federal oversight of activity, this sort of regulation of existing commerce is
constitutional.182
C. States’ Plenary Police Power vs. the Commerce Clause
The proposed federal prescriber education requirement mandates professional
training for state-licensed practitioners who prescribe controlled substances. This
requirement is permitted under the Commerce Clause, but also does not undermine
the regulation of medical practice reserved to the states because, as shown in the
following cases, core provisions of the CSA have survived challenges based on
states‘ plenary police power. For instance, in United States v. Collier and United
States v. Rosenberg, the Fifth and Ninth circuits, respectively, established the
constitutionality of regulations under the CSA and asserted that such regulations do
not invalidate the states‘ police powers to regulate medicine.183
In Collier, Dr. Henry M. Collier appealed his conviction under the CSA for
distributing methadone outside of the usual course of his professional practice
based on his improper prescribing of methadone, which is a synthetic opioid. 184 He
specifically attacked § 841(a)(1) of the CSA, which applies criminal sanctions to

180. See supra note 154 and accompanying text.
181. See Nat’l Fed’n of Indep. Bus., 132 S. Ct. at 2587.
182. For example, state police powers traditionally include regulation of motor vehicles, but in 1986,
the federal government passed the Commercial Motor Vehicle Safety Act to ensure that drivers of large
vehicles are qualified to do so, and to remove unsafe large-vehicle drivers from highways. Commercial
Driver’s License Program (CDL/CDLIS), FED. MOTOR CARRIER SAFETY ADMIN., U.S. DEP‘T OF
TRANSP., http://www.fmcsa.dot.gov/registration-licensing/cdl/cdl.htm (last visited May 9, 2013).
Because states had varying rules regarding drivers of large trucks and buses and could not adequately
regulate large vehicles moving between states, it was necessary for the federal government to involve
itself. Id. Like the CSA Amendment proposed in this Article, the federal commercial drivers‘ license
retained the states‘ authority to issue drivers licenses, but required that states meet minimum
requirements. Id.
183. United States v. Collier, 478 F.2d 268, 272–74 (5th Cir. 1973); United States v. Rosenberg, 515
F.2d 190, 197–98 (9th Cir. 1975).
184. 478 F.2d at 270.
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physicians for unlawfully prescribing and dispensing controlled substances. 185 He
argued that the provision ―violate[d] the Tenth Amendment by invading the state‘s
residual police power to control medical practice‖ because the provision does not
require a showing that the conduct of individual acts affected interstate
commerce.186 The court held that § 801 constituted a permissible exercise of
Congress‘s powers under the Commerce Clause because Congress itself had
already specifically determined that local distribution and possession of controlled
substances have a substantial and direct effect upon interstate commerce. 187
Therefore, the only issue on appeal was whether the CSA allowed the federal
government to regulate activity without encroaching on states‘ authority. 188 The
court found that the CSA was directly targeted at physicians, such as Dr. Collier,
who legally had the privilege under state law to prescribe drugs. 189 The purpose of
the CSA was partially to stop individuals from diverting controlled substances from
legitimate channels to the illicit market. 190 The CSA did this by creating a closed
system that regulated those with access to controlled substances, including statelicensed professionals.191 The court noted that ―Congress could reasonably decide
that in order to effectively regulate interstate commerce in drugs, it is necessary to
insure that persons within legitimate distribution channels, including dispensing
physicians . . . , [do] not divert drugs into the illicit market.‖ 192 The court found that
the provision did not encroach on states‘ plenary police power. 193
In Rosenberg, undercover agents executed a successful sting operation in Dr.
Maurice W. Rosenberg‘s office for prescribing controlled substances upon patients‘
requests for such medication, without performing an examination or determining
whether his patients had a legitimate medical need for such medications. 194 A jury
convicted Dr. Rosenberg of twenty-seven counts of illegally distributing Schedule
II, III, and IV substances under the CSA. 195 He appealed with a number of
constitutional claims, including an assertion that, under the Tenth Amendment,
only the state of California could determine whether his acts were appropriate,
based on the state‘s purview over medical practice.196 He argued that the language
in the CSA provision indicated Congress‘s intent that the federal government rely
185. Id.; see also 21 U.S.C. § 841(b) (2011) (listing penalties for violating the CSA).
186. Collier, 478 F.2d at 272.
187. Id. at 273.
188. Id.
189. Id.
190. Id.
191. Id.
192. Id.
193. Id. at 272–73.
194. United States v. Rosenberg, 515 F.2d 190, 191 (9th Cir. 1975).
195. Id. at 191–92.
196. Id. at 198. Dr. Rosenberg claimed that the federal government must rely on the state of
California‘s concept of acts within the course of professional practice because medical practice is under
the purview of the states. Id.
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on a state determination.197 The court noted that the Tenth Amendment was a
truism, and that, although the state clearly has the power to regulate controlled
substances, the federal government also has concurrent, regulatory power under
both its taxing authority and the Commerce Clause. 198
More recently, objections were made on Tenth Amendment grounds to a
proposed CSA Amendment, under the Pain Relief Promotion Act of 1999. 199 That
legislation sought to amend the CSA to prohibit the use of controlled substances for
physician-assisted suicide, after the State of Oregon passed the Death with Dignity
Act.200 Dissenters argued that the Act, H.R. 2260, would federalize the practice of
medicine, which had always been the purview of the states. 201 States would not be
free to act as laboratories of democracy. 202 Further, opponents argued that another
potential side effect of this legislation was the ―politicization of medical
standards.‖203 Ultimately, this bill failed.204
Applying the Collier and Rosenberg precedents, a constitutional challenge
against the prescriber education requirement based upon a plenary police power
argument does not hold up.205 Whereas the CSA provisions upheld in these cases
allow the federal government to regulate local activity, the prescriber education
requirement would be less invasive of states‘ plenary police power to control the
practice of medicine.206 In the face of the prescription drug epidemic, instead of
reserving all discretion to the federal government, the prescriber education
requirement would empower states to come up with their own professional training
standards targeted to better combat the diversion of prescription drugs within the
boundaries of each state.
197. Id.
198. Id. at 198.
199. H.R. REP. NO. 106–378 (1999).
200. Id.
201. Id.
202. Id.
203. Id.
204. See Senate Adjourns Without Acting on the Pain Relief Promotion Act Bill, THE BODY.COM
(Spring 2001), http://www.thebody.com/content/art16728.html (noting that the Pain Relief Promotion
Act did not pass due to public opposition and controversy).
205. See United States v. Collier, 478 F.2d 268, 272–73 (5th Cir. 1973) (holding that a CSA
provision making it illegal for physicians to dispense certain controlled substances directly to users other
than ―in the course to his professional practice‖ did not invade states‘ residual police powers under the
Tenth Amendment); United States v. Rosenberg, 515 F.2d 190, 198 (9th Cir. 1975) (finding that
Congress has the power to regulate drug dispensation and that such regulation does not violate the Tenth
Amendment).
206. Compare Rosenberg, 515 F.2d at 198 (providing that Congress may regulate drug dispensation
under the Interstate Commerce Clause), with California v. United States, 104 F.3d 1086, 1093 (9th Cir.
1997) (holding that an independent constitutional obligation to provide alien children with an education
did not implicate the Tenth Amendment‘s preservation of the states‘ plenary police power), with
Burroughs v. Dep‘t of the Army, 445 F. App‘x 347, 349–50 (Fed. Cir. 2011) (holding that Congress has
the ability to draft into statutes minimum education requirements for positions requiring scientific or
technical knowledge).
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The dissenters‘ words regarding the Pain Relief Promotion Act of 1999 can
be used to promote the prescriber education requirement. 207 The 1999
congressional report stated that ―[b]ecause the optimal approach is often not clear,
our Federal system encourages States to try different approaches. With local
variations, the country can discover the best course of action.‖ 208 The prescriber
education mandate would require states‘ active lead to create medical standards,
which would promote states‘ police power over health and safety. Therefore, the
requirement would respond to a national crisis, but respect each state‘s jurisdiction
to create and implement standards for prescriber education, fit to local concerns and
preferences.
V. ATTEMPTS AND RECOMMENDATIONS FOR A PRESCRIBER EDUCATION
REQUIREMENT
Practitioner education is not only a means of reducing practitioner liability; it
is also a necessary step in addressing the prescription drug abuse epidemic. This
section reviews the few states that currently have legislation on prescriber
education, and a recent federal attempt to require education for prescribers of
controlled substances.
A. State Legislation Requiring Specific Controlled Substance Education for
Licensure
State licensing boards determine requirements for initial professional
licensing and for license renewal in each state. Most states require continuing
practitioner education for periodic relicensure. 209 A handful of states have created
laws aimed at educating practitioners in controlled substance prescribing as part of
licensure or re-licensure. California and Oregon require that prescribers complete a
one-time pain management course.210 Michigan requires pain and symptom
management training for re-licensure.211 Massachusetts requires effective pain
management training to obtain or renew a license. 212 Tennessee requires one of
forty relicensure education hours to be in safe prescribing practices. 213 Other states,
including Ohio, Rhode Island, and Texas, recommend pain management training or

207. See H.R. REP. NO. 106–378 (arguing that health professionals should have the ―knowledge and
discretion‖ to avoid unintentional distribution of drugs).
208. Id. (quoting Pain Relief Promotion Act of 1999: Hearing on H.R. 2260 Before the Subcomm. on
Const., 106th Cong. (1999) (statement of David Orentlicher, Dir., Ctr. of Law & Health, Ind. Univ. Sch.
of Law, at 5)).
209. See AM. MED. ASS‘N, STATE MEDICAL LICENSURE REQUIREMENTS AND STATISTICS 65, 67
(2013).
210. CAL. BUS. & PROF. CODE § 2190.5 (West 2013); OR. REV. STAT. § 413.590(1) (2011).
211. MICH. COMP. LAWS ANN. § 333.16204(1) (2008).
212. MASS. GEN. LAWS ANN. ch. 94C, § 18(e) (West Supp. 2012).
213. TENN. COMP. R. & REGS. 0880-02–.19(1)(b) (2010).
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include it as one of the options for mandatory relicensure training. 214 New Mexico
requires all physicians with federal controlled-substance registrations to take five
hours of continuing education on pain management each year, including lessons on
the pharmacology and risks of controlled substances, and information about the
problems of abuse, addiction, and diversion of medicine. 215
Yet, these few states with their varying requirements are not enough. 216 Even
if more states respond to the problem by enacting legislation, only a comprehensive
solution in which every state requires every practitioner to receive mandatory
training on prescribing controlled substances can succeed. Short of a federal
mandate, illicit abusers can obtain prescription drugs from neighboring states with
fewer or less specific prescriber controls.217
B. The FDA Opioid REMS
Congress granted the U.S. Food and Drug Administration (FDA) authority to
enact Risk Evaluation and Mitigation Strategies (REMS) as part of the Food and
Drug Administration Amendments Act of 2007 (FDAAA). 218 The FDAAA
authorized the FDA to require pharmaceutical manufacturers to propose strategies
to mitigate certain risks of drugs that have a high or suspected high risk of abuse
and overdose.219 The FDA may impose REMS to ensure that the benefits of a drug
continue to outweigh the risks.220

214. OHIO ADMIN. CODE 4731-21-03 (2012) (encouraging practitioners who regularly treat patients
with intractable pain to complete pain management coursework); 41-31 R.I. CODE R. § 6.2.1
(LexisNexis 2013) (establishing that a list of continuing education topics on ―current public health
needs‖ shall be published); Physician Licensing: Frequently Asked Questions, R. I. DEPT. OF HEALTH,
http://www.health.ri.gov/publications/frequentlyaskedquestions/PhysicianLicensing.pdf (last visited
May 10, 2013) (including pain management as a continuing education topic); TEX. OCC. CODE ANN. §
156.055 (West 2012) (encouraging practitioners who treat pain patients to include continuing medical
education in pain treatment).
215. N.M. CODE R. § 24-2D-5.1 (LexisNexis 2012); see also Kate Nash, Medical Board OKs New
Rules to Combat Prescription Drug Abuse, NEW MEXICAN (Aug. 10, 2012),
http://www.sfnewmexican.com/Local%20News/081112medboard#.UWV87rVax2B.
216. See supra notes 209–15; see also MedScape News Today, A Guide to State Opioid Prescribing
Policies, http://www.medscape.com/resource/pain/opioid-policies (last visited May 20, 2013)
(illustrating variations in opioid prescription regulation among states).
217. See Amy L. Cadwell, In the War of Prescription Drug Abuse, E-Pharmacies Making Doctor
Shopping Irrelevant, 7 HOUS. J. HEALTH L. & POL‘Y 85 ,120–22 (2007) (explaining current gaps in
federal and state laws designed to prevent prescription drug abuse and emphasizing the need for a
controlling federal mandate).
218. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823
(2007). The FDA‘s Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting
Opioids is an effort to reduce risks of these drugs by introducing new safety measures. See Approved
Risk Evaluation and Mitigation Strategies (REMS), U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm1
11350.htm (last updated May 29, 2013).
219. 21 U.S.C. § 355-1 (2011).
220. Id.
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As originally contemplated when proposed, the REMS for long-acting and
extended release opioids had a stringent education requirement for prescribers. 221
But, the resulting opioid REMS, finalized in 2012, has a much less stringent
education requirement.222 Prior to the opioid REMS finalization, two FDA advisory
committees overwhelmingly agreed that the opioid REMS cannot meet its purpose
to decrease abuse, misuse, addiction, and overdose deaths from improper use of
opioid medication unless it requires mandatory prescriber education regarding safe
prescribing and abuse detection.223 However, the final REMS compels
manufacturers of long-acting and extended-release opioids to provide product
warnings to patients and offer only voluntary education programs for opioid
prescribers.224 The voluntary training program will most likely be carried out
through manufacturer grants to recognized continuing medical education groups
that will be required to obtain FDA approval of their educational materials. 225 This

221. Id. In April 2009, the FDA published a notice for public meeting dates to discuss a REMS for
certain opioid drugs, such as fentanyl, hydromorphone, methadone, morphine, oxycodone, and
oxymorphone. Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs, 74 Fed. Reg. 17969
(Apr. 20, 2009). The Federal Register announcement requested comments on the type of education that
should be provided and how the certification should be administered. Id. The FDA conducted a lengthy
process for comment—spanning three years—to elicit feedback from the public, physicians, and
manufacturers on its planned opioid REMS. See Questions and Answers: FDA approves a Risk
Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid
Analgesics, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/Informationby
DrugClass/ucm309742.htm (last updated Apr. 26, 2013) (explaining the various public meetings that
FDA held between 2009 and 2011 to receive REMS feedback).
222. Compare supra note 221 and accompanying text (discussing the lengthy process which the
FDA underwent to receive feedback on the best approach to educating prescribers), with ExtendedRelease (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)
U.S. FOOD & DRUG ADMIN., 22 (2013), http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket
DrugSafetyInformationforPatientsandProviders/UCM311290.pdf (describing the current setup for the
REMS education program).
223. See John F. Peppin et al., Issues and Critiques of the Forthcoming Risk Evaluation and
Mitigation Strategy (REMS) for Opioids in Pain Management, 27 ISSUES L. & MED. 91, 102–06 (2012)
(enumerating the various reasons the FDA committee cited in approving or disapproving the Opioid
REMS). Even advisory committee members who voted for the proposed REMS commented that it
would not be able to address the problem, saying, ―I voted yes not because I think it will work but
because I think it will fail and that will force a new look at this serious problem.‖; ―REMS is severely
flawed and I agree with all the people who voted ‗No,‘ but I think we need to start somewhere.‖
Comments from the ―No‖ group included, ―. . . we are proposing action on people not involved in the
problem.‖; ―This group needs to send a message to Congress that what they‘re getting from FDA is
insufficient; the DATA 2000 is a good model of what needs to be done here.‖ Id.; see also CTR. FOR
LAWFUL ACCESS & ABUSE DETERRENCE, supra note 1, at 19 (stating that committee members advised
the FDA that mandatory education for prescribers should be a primary component of any REMS
program).
224. See Thomas Sullivan, FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS)
for Extended Release/Long Acting Opioids Including a Prescriber Education Program, POL‘Y & MED.
(July 9, 2012), http://www.policymed.com/2012/07/fda-releases-final-risk-evaluation-and-mitigationstrategies-rems-for-extended-releaselong-acting-opioids-including-a-pres.html (describing the FDA‘s
voluntary education program for prescribers, including the lack of mandatory training).
225. See id. (discussing the expectation that companies will provide educational grants).
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program is consistent with the fact that FDA is not authorized to regulate prescriber
behavior or professional practice.226 But, because of this limitation, the opioid
REMS does not properly target those who must change their behaviors to stop the
epidemic.227 Responsible prescribers, who would be most likely to participate in
such voluntary training, usually already have the resources and the know-how to
avoid contributing to the problem.
The REMS is still useful because, under the ―learned intermediary doctrine,‖
when a manufacturer warns a practitioner of the risks of a drug, the practitioner
then has the duty to convey the warning to patients. 228 Although the REMS does
not go far enough, the opioid REMS will place a heightened duty on practitioners,
suggesting one further reason for practitioners to undergo training. 229
C. Buprenorphine as a Model for Education Requirements
The Drug Addiction Treatment Act of 2000 (DATA 2000) specifically
requires that practitioners take eight hours of state courses to prescribe certain
controlled substances in the office setting. 230 Similarly to this Article‘s prescriber
education proposal, except relating only to opioid addiction treatment medications
rather than to all controlled substances, this currently enacted law is a viable
regulation on practitioners.231 DATA 2000 requires education for prescribers of
Schedule III, IV, and V opioid addiction treatment medications, including
buprenorphine.232 Prescribers can waive the requirement by proving prior education
through relevant certifications or other training in prescription medication abuse
detection and deterrence.233
Much of the justification for federal registration to prescribe buprenorphine is
applicable to a general controlled substance prescriber education requirement. The
DATA 2000 House report justified its authority as an exercise of the Commerce

226. Cf. U.S. FOOD & DRUG ADMIN., FDA Authority, in REGULATORY PROCEDURES MANUAL 2-1,
2-2–2-40 (2012), available at http://www.fda.gov/downloads/ICECI/ComplianceManuals/Regulatory
ProceduresManual/UCM074340.pdf (providing an overview on FDA‘s statutory authority, none of
which provides authority to regulate prescriber behavior or professional practice).
227. Cf. First Opioid Voluntary REMS Training Goes Live, ANESTHESIOLOGY NEWS (Mar. 22,
2013), http://www.anesthesiologynews.com/ViewArticle.aspx?d=Web%2BExclusives&d_id=175&i=
March+2013&i_id=937&a_id=22833 (discussing how the FDA urges prescribers to take advantage of
the opioid prescribing, implying that REMS does compel such prescribers to take the training).
228. Kennedy v. Medtronic, Inc., 851 N.E.2d 778, 784 (Ill. App. Ct. 2006) (quoting Kirk v. Michael
Reese Hosp. & Med. Ctr., 117 Ill. 2d 507, 517 (1987).
229. See First Opioid Voluntary REMS Training Goes Live, supra note 227 (stating that the FDA
envisions prescribers ―taking advantage of training opportunities on opioid therapy‖ to be a key role for
prescribers in helping to curtail opioid abuse).
230. 21 U.S.C. § 823(g) (2011).
231. See Peppin et al., supra note 223, at 103 tbl.3 (including comments from joint FDA advisory
committee members that opioid education be modeled after the buprenorphine framework).
232. § 823(g).
233. Id.
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Clause.234 The DATA 2000 House report cited the 600,000 heroin users in need of
addiction treatment and the costs of heroin addiction to families and
communities.235 It suggested that the framework in place under the CSA should be
used to further regulate certain controlled substances with risks of abuse. 236
Similar to the justification for DATA 2000, the current CSA prescriber
registration system can be used as the framework for a mandatory prescriber
education program at a relatively low cost. 237 Under the public interest theory of
economic regulation, in the midst of a market failure due to information
asymmetry, Congress should act.238 In the case of pharmaceuticals, information
asymmetry occurs when manufacturers and government have more information
about the appropriateness or the effectiveness of medications than prescribers and
patients.239 The costs of this asymmetry in the prescription drug epidemic are
enormous. Abuse of opioid pain relievers costs health insurers $72.5 billion
annually in direct health care costs. 240 Thus, if Congress were to complete a cost
benefit analysis, the need for legislation similar to DATA 2000 that covers all
controlled substance prescribing would be clear.
D. The Rockefeller Bill
Realizing the need for such legislation, United States Senator Jay Rockefeller
of West Virginia introduced the Prescription Drug Abuse Prevention and Treatment
Act to the Senate in March 2011 and, after the 2011 bill failed to pass, reintroduced
the bill in 2013.241 The bill includes a workable, mandatory prescriber education
component.242 Under the prescriber education provision, the CSA would be
amended to require physicians to complete sixteen hours of training every three
years in order to prescribe methadone or other controlled substances. 243 The
234. H.R. REP. NO. 106–441 (1999).
235. Id.
236. Id.
237. § 823(g) (requiring qualified practitioners dispensing drugs for narcotic treatment to register
annually).
238. See SUSAN E. DUDLEY & JERRY BRITO, REGULATION: A PRIMER 12–14 (2d ed. 2012), (stating
that the public interest theory suggests that markets are usually efficient in allocating scarce resources,
but, under certain circumstances, may fail, thus requiring politicians to intervene and regulate to serve
the public interest).
239. See SARA BENNETT ET AL., WORLD HEALTH ORG., PUBLIC-PRIVATE ROLES IN THE
PHARMACEUTICAL SECTOR: IMPLICATIONS FOR EQUITABLE ACCESS AND RATIONAL DRUG USE 22–23
(1997), available at http://apps.who.int/medicinedocs/pdf/whozip27e/whozip27e.pdf (arguing for
government intervention in the pharmaceutical market on the ground that it is subject to informational
imbalance because prescribers and patients are less informed about drug efficacy than manufacturers).
240. COAL. AGAINST INS. FRAUD, PRESCRIPTION FOR PERIL 38 (2007), available at
http://www.insurancefraud.org/downloads/drugDiversion.pdf.
241. Prescription Drug Abuse Prevention and Treatment Act of 2011, S. 507, 112th Cong. (2011);
Prescription Drug Abuse Prevention and Treatment Act of 2013, S. 348, 113th Cong. (2013).
242. S. 348.
243. Id.
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training would be provided by an expert medical pain society244 and would
specifically cover: ―(i) the treatment and management of opioid-dependent patients;
(ii) pain management treatment guidelines; and (iii) early detection of opioid
addiction, including through such methods as Screening, Brief Intervention, and
Referral to Treatment (SBIRT).‖245 Enforcement would be funded through use of a
portion of the DEA registration fee for prescribers. 246
The current Rockefeller bill could be amended by focusing solely on the
prescriber education component and by including specific training requirements on
the risks of all controlled substances, not just opioids.247 Moreover, the current bill
does not mention implementation by the states, so it would probably be
administered directly through the federal government. 248 Instead, the bill should
suggest that the prescriber education be carried out through the existing state
education framework for practitioners. 249 Additionally, the mandatory controlled
substances education should be required to occur before a practitioner can register
to prescribe these substances in addition to later training.250
In sum, this Part of the Article gives examples of attempts at educating
prescribers in controlled substance prescribing that can be used to inform how the
proposed CSA Amendment should be formulated.

244. Id. Under the proposed bill, the training would be provided by:
the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the
American Medical Association, the American Osteopathic Association, the American Psychiatric
Association, the American Academy of Pain Management, the American Pain Society, the American
Academy of Pain Medicine, the American Board of Pain Medicine, the American Society of
Interventional Pain Physicians, or any other organization that the Secretary determines is appropriate
for purposes of this subparagraph.
Id.
245. Id. SBIRT is aimed at stopping substance abuse before it becomes serious. Rebecca A. Clay,
Screening, Brief Intervention, and Referral to Treatment: New Populations, New Effectiveness Data,
SAMSHA News (SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., ROCKVILLE, MD.), Nov.Dec. 2009, at 1, 1. Patients in health care venues are quickly screened to assess their alcohol and drug
use. Id. at 2. If they are deemed at risk, they receive an intervention to ―rais[e] their awareness of
substance abuse and motivate[e] them to change their behavior.‖ Id.
246. S. 348.
247. Larry K. Houck, Legislative Fixes Focus on Controlled Substance Issues, FDA Law Blog (Mar.
22, 2011), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2011/03/legislative-fixes-focus-oncontrolled-substance-issues.html. Described as ―ambitious,‖ the bill takes on seven opioid prescribing
topics. Id. Beyond the prescriber education piece, the bill includes: consumer education, a moratorium
on large dose methadone hydrochloride tablets, access requirements for opioid treatment programs,
clinical standards for controlled substances, state drug monitoring program requirements for answering
drug enforcement information requests, and mortality reporting. See S. 348, supra note 241, §§ 3–8.
Detractors of the further reach of drug enforcement would especially dislike the component requiring
that state prescription monitoring programs receiving federal money in exchange for compliance with
drug enforcement information requests. See id. §8.
248. See generally S. 348, supra note 241 (making no mention of state implementation of S. 507).
249. See discussion infra Part VI.A.
250. See infra Part VI.A.
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VI. THE NECESSARY SOLUTION: PRACTICAL COMPONENTS OF THE FEDERAL
STATUTE
Under current state health systems, requirements for initial medical licensing
vary by state.251 For medical license renewal, most states require practitioners to
complete continuing medical education. 252 The average number of state-mandated,
continuing medical education credits per year range from fifteen to fifty credits. 253
Many states have further requirements for the content of these credits. 254
This Part first makes recommendations for the proposed Amendment. Then it
uses Massachusetts, a state that already requires controlled substance education for
prescribers, as a model to show how the new federal requirement would be
seamless.255 It uses Virginia, a state that currently requires continuing medical
education, but does not require education for controlled substance prescribers, as a
model for how the new mandate would fit into a system that currently does not
require such training.256 It also looks at states that have no continuing medical
education requirements to see how such a mandate would work in those states. 257
A. Specific Recommendations for the Prescriber Education Requirement
The prescriber education requirement could be inserted as Section 3 of 21
U.S.C. § 823(g).258 It could be modeled particularly after the current education
component in the Rockefeller bill259 and the buprenorphine prescriber education
requirements.260 Like the buprenorphine waiver, prescribers with demonstrated
knowledge or training should be exempted from further requirements. 261
Competence in an area may be demonstrated through awarded recognition or by

251. See State-Specific Requirements for Initial Medical Licensure, Fed‘n of State Med. Bds.,
http://www.fsmb.org/usmle_eliinitial.html (last updated Aug. 2012) (outlining the differences in medical
licensure requirements among states).
252. See AM. MED. ASS‘N, supra note 209, at 67–69 tbl.21 (listing state-specific continuing medical
education requirements).
253. See id.
254. See id. (finding, for example, that Iowa requires training for ―identifying and reporting child
and abuse,‖ and Kentucky requires two credits on HIV/AIDS every ten years).
255. See infra Part VI.B.
256. See infra Part VI.C.
257. See infra Part VI.D.
258. See 21 U.S.C. § 823(g) (2011) (stating practitioner requirements for dispensing narcotic drugs
for treatments).
259. Prescription Drug Abuse Prevention and Treatment Act of 2013, S. 348, 113th Cong. § 4
(2013).
260. § 823(g).
261. See id. (stating that qualifying physicians can receive a waiver to practice opioid addiction
therapy if the physician has completed at least eight hours of specific training).
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those who have a specific medical certification, such as pain medicine or addiction
medicine, or recognized specialty such as anesthesiology. 262
The prescriber education mandate should require controlled substance
education before a prescriber can register with the DEA to prescribe controlled
substances, as well as for registration renewal. 263 Practitioners taking courses in
safe controlled substance prescribing and abuse prevention while attending an
accredited medical school should be deemed to meet the initial education
requirement for prescribing controlled substances. 264 When crafting the legislation,
experts should determine a minimum number of course hours necessary per
registration term for prescribers of controlled substances. The safe prescribing and
abuse prevention courses should be integrated into education courses practitioners
already must take to meet state licensing requirements, without taking more courses
than they already take for licensure. State licensing boards should approve the
specific content of the controlled substances education program for each class of
prescribers (i.e., physicians, physician assistants, and nurse practitioners) in their
state and could require further hours than federally mandated, if preferred to meet
state licensure or controlled substance prescribing standards. 265
The prescriber education legislation should also add a section under 21 U.S.C.
§ 843 of the CSA on prohibited acts, which would prohibit misstatement of facts to
the DEA regarding prescriber controlled substance education. 266 The penalties
currently in force in that section would then apply. 267 As with most actions under
the CSA against prescribers, the DEA would investigate controlled substance
prescribers‘ compliance based on tips or complaints that usually emanate from the
state.268 In investigating complaints, the DEA should work with the relevant state
medical board to determine whether the federal documentation requirements for
controlled substance education were met. For instance, in Virginia, pursuant to an
investigation request, the process for obtaining the physician‘s documentation of
training could be similar to what is now utilized for the random auditing process for
continuing medical education. 269 As included in the Rockefeller bill, funding for

262. See id. (stating that a physician is considered qualified if the physician holds a board
certification in addiction psychiatry from certain medical organizations).
263. See supra Part II.A.
264. See supra Part II.A.
265. See supra Part III (discussing the states‘ authority to regulate the practice of medicine pursuant
varying state controlled substances acts).
266. See 21 U.S.C. § 843 (2011) (discussing the unlawful acts that a prescriber may commit, but
failing to make a misstatement of the facts by the prescriber unlawful).
267. § 834(d)(i).
268. See H.R. REP. NO. 106-378 (1999) (stating that civil actions revoking a practitioner‘s license
are hardly ever initiated by the DEA because usually, state action precipitates DEA initiation of a civil
action).
269. 18 VA. ADMIN. CODE § 85-20-235(D) (2012) (detailing the continued competency requirements
for renewing an active medical license).
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enforcement could be drawn from a portion of the prescriber registration fees or it
could be drawn through funding currently available for DEA enforcement. 270
B. Massachusetts as a Model
In Massachusetts, prescribers must take one hundred credits of continuing
professional development every two years with at least forty hours in Category 1,
which are courses accredited by certain medical organizations listed in the
Massachusetts statute.271 Massachusetts also has various stipulations on the content
of the continuing education. At least fifty-one of the credits must be in the
practitioner‘s primary areas of practice, with additional requirements of ten hours in
risk management, two hours focusing on the board‘s regulations, and two hours in
end-of-life-care issues.272
Moreover, Massachusetts is one of the few states that already requires pain
management and opioid education before practitioners initially receive or renew
their professional license. Three education hours must encompass ―(i) effective
pain management; (ii) identification of patients at high risk for substance abuse;
and (iii) counseling patients about the side effects, addictive nature, and proper
storage and disposal of prescription medications.‖ 273 The law directs each related
licensing board to develop appropriate standards for such training. 274 Massachusetts
offers a free online course that meets the statutory education requirement. 275
Enactment of a new federal education requirement would likely fit seamlessly
into Massachusetts‘ current education scheme because Massachusetts has robust
prescriber education requirements. 276 If the federal requirements were more
stringent or required further hours of controlled substance education on average per
year, Massachusetts practitioners would need to meet the further federal
requirements that go beyond the current state scheme.

270. Prescription Drug Abuse Prevention and Treatment Act of 2013, S. 348, 113th Cong. § 4(d)
(2013).
271. 243 MASS. CODE REGS. 2.06(6)(a)(1) (2012).
272. 2.06(6)(a), (b), (h).
273. MASS. GEN. LAWS ANN. ch. 94C, § 18(e)(i)–(iii) (West Supp. 2012).
274. §18(e)(iii).
275. Safe and Effective Opioid Prescribing for Chronic Pain, OPIOIDPRESCRIBING.COM,
http://www.opioidprescribing.com (last visited June. 3, 2013) (offering a series of online presentations
through the Boston University School of Medicine regarding how clinicians can work with patients
living with chronic pain).
276. 243 MASS. CODE REGS. 2.06(6)(d) (2012) (describing Massachusetts‘ educational requirements
for renewing a controlled substance prescriber license, which includes requiring licensees to take
training courses in identifying patients at high risk for abuse and counseling patients on the side effects
and addictive nature of prescription medicines).
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C. Virginia as a Model
The Virginia Board of Medicine requires sixty hours of ―continued
competency requirements‖ every two years. 277 Practitioners are free to determine
the contents of the curriculum, with the following few restrictions. 278 The Board
requires at least thirty ―Type 1‖ hours in ―activities or courses offered by an
accredited sponsor or organization sanctioned by the profession.‖279 The rest of the
Virginia credits may be ―Type 2,‖ which are ―chosen by the licensee to address
such areas as ethics, standards of care, patient safety, new medical technology, and
patient communication.‖280 These may be earned through self study, medical
publications, attending professional meetings, learning new procedures, sitting on
medical ethics panels, and so forth.281 Newly licensed physicians are exempted
from the sixty-hour requirement.282
In Virginia, physicians who are not trained in prescribing controlled
substances while in medical school can still obtain their medical licenses. 283 No
further medical education is required for licensure until completing the
requirements for re-licensure by the fourth year of practice.284 Under the prescriber
education requirement, Virginia practitioners desiring to prescribe controlled
substances would need to complete an education course designed or recognized by
Virginia. The Virginia Board of Medicine would need to ensure that Virginia‘s
available courses meet the educational standard for registration under the CSA. The
training would need to occur before initial controlled substance registration and as
part of a practitioner‘s required sixty hours of training every two years. 285
Prescribers who have taken a qualifying class in medical school before initial
licensure or who are otherwise specifically recognized, certified, or of a qualifying
specialty, would be deemed to satisfy the requirement.
D. States Without Continuing Medical Education Requirements
Some states do not currently require continuing medical education at all.
Colorado, Indiana, Montana, New York, South Dakota, and Vermont have no
requirement, although Vermont has new legislation that will go into effect in

277. 18 VA. ADMIN. CODE § 85-20-235(A) (2012).
278. Id.
279. Id.
280. Id.
281. See Frequently Asked Questions for the Virginia Board of Medicine, VA. BD. OF MED.,
http://www.dhp.virginia.gov/medicine/medicine_faq.htm#continuing (last visited May 10, 2013).
282. § 85-20-235(B).
283. See supra notes 277–82 and accompanying text (discussing educational requirements for
practitioners in Virginia).
284. § 85-20-235(B) (indicating that a newly-licensed practitioner is exempt from training
requirements associated with a license renewal for the first two-year period; therefore, the next required
re-licensure would occur four years after the initial medical license was received).
285. See id.
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2014.286 Although state-specific education efforts targeting the local environment
are preferable, the prescriber education requirement could include stipulations
allowing prescribers in states without education requirements to substitute a
program from a nationally accredited program recognized under the federal law.
Like the Rockefeller bill, the CSA amendment could defer to the judgment of
credible medical organizations, such as the American Medical Association, the
American Society of Anesthesiologists, and the American Society of Addiction
Medicine, in defining the programs in addition to those that are state approved.287
VII. BENEFITS OF THE PROPOSED PRESCRIBER EDUCATION REQUIREMENT:
EDUCATION TO EMPOWER PHYSICIANS TO PRESCRIBE APPROPRIATELY,
IMPROVE PATIENT TREATMENT, AND REDUCE LIABILITY
An education requirement, through the longstanding, stable, state-regulated
health systems, recognizes the importance of protecting states‘ rights to govern the
practice of medicine and other professions. 288 The epidemic status of the
prescription drug abuse problem suggests that swift, coordinated action among
government authorities is necessary.289
Opponents of an education mandate suggest that such a requirement would
make prescribers fearful of criminal liability, and that it would cause many
practitioners to eliminate controlled substance prescribing from their practices. 290
The resulting reduction in numbers of prescribers, in turn, is purported to limit
access to medications for patients suffering with pain or other conditions for which
controlled substances are prescribed.291 On the contrary, educated physicians can
make healthier prescribing decisions for patients and will counsel patients on
proper use of controlled substances. 292 Rather than reducing access to controlled
substances, practitioners will be empowered through training to prescribe drugs

286. See AM. MED. ASS‘N, supra note 209, at 67–69 tbl.21.
287. See supra note 244 and accompanying text.
288. See supra Part IV.C.
289. See supra notes 2–9 and accompanying text.
290. See, e.g., Hoffmann, supra note 40, at 234–35 (stating that the law enforcement climate for
opioid prescribing is causing the prescriber pool to dwindle); Johnson, supra note 43, at 1029–30
(stating the impact of changes in treatment practices resulting from opioid investigations); see also
Opioid REMS Industry Working Group Meeting with Stakeholders, U.S. FOOD & DRUG ADMIN. 16, 34,
68 (Nov. 18, 2009), http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm
193696.pdf (featuring slides from the FDA stakeholder meeting and the Industry Working Group
meeting in late 2009 that suggests that attendees believed that a mandatory education requirement would
result in limiting patient access to opioids, especially in rural areas and for already vulnerable
populations including the poor, people of color, and women).
291. See sources cited supra note 290.
292. See supra Part II.B.
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without fear.293 Those unwilling to obtain education in safe prescribing pose a
threat to patients and should not be prescribing controlled substances. 294
Controlled substance prescribers who follow their state-based training can
take comfort in learning medical board investigation practices and negligence case
law, which protect practitioners who implement reasonable precautions to prevent
diversion, misuse, and abuse. 295 Accordingly, practitioners who complete training
programs and follow state guidance should have a strong defense if they ever face
an investigation or a prescribing liability case. 296
Opponents of practitioner education suggest agreement on controlled
substance prescribing standards is impossible because of the varying opinions in
the medical community.297 Physicians do face uncertainty when even experts
cannot agree. But inaction will not solve the problem for patients, practitioners, or
the public. The reasonable care standard for physicians is defined as the standard
recognized by other professionals in the community. 298 State-based education
programs present an opportunity to develop appropriate standards for different
locales and situations.299 It is important that prescribers take steps to educate
themselves so that they can stay abreast of evolving standards and shield
themselves from liability.300
Without a workable solution to the prescription drug abuse epidemic, patients,
prescribers, and manufacturers may face even tighter controls that could further
threaten the availability and marketability of medications that have potential for
diversion, misuse, and abuse.301 With proper training, physicians will be able to
prescribe (or not prescribe) with confidence. 302 Greater education and certainty will
increase access to medications for legitimate patients, equip physicians to better
educate those patients, and reduce physicians‘ chances of liability for inappropriate
prescribing.303

293. See supra Part II.B.
294. See supra Part II.B.
295. See supra Part II.B.
296. See supra Part II.B.
297. See Hoffmann, supra note 40, at 291 (discussing the high variability and vagaries of current
prescriptive practices that have led to confusion among practitioners).
298. See supra note 45 and accompanying text.
299. See supra Part V.A.
300. See supra Part II.A–B.
301. See Meier, supra note 24 (discussing the tightening of controls for prescribing opioids in
Washington as a result of misuse and abuse).
302. See supra Part II.B.
303. See supra Part II.B.
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VIII. CONCLUSION
The federal government must take action aimed directly at the reducing the
diversion of prescription medications. Enacting a mandatory prescriber education
requirement under the CSA that respects states‘ plenary police powers and that is
consistent with the federal government‘s authority under the Commerce Clause and
Necessary and Proper Clause can properly address this epidemic at the first point of
failure: where a physician improperly writes a prescription for a controlled
substance because he or she does not know any better.

